0001493152-23-016425.txt : 20230511 0001493152-23-016425.hdr.sgml : 20230511 20230511165536 ACCESSION NUMBER: 0001493152-23-016425 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Co-Diagnostics, Inc. CENTRAL INDEX KEY: 0001692415 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 462609396 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38148 FILM NUMBER: 23911923 BUSINESS ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 BUSINESS PHONE: 8012789769 MAIL ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 10-Q 1 form10-q.htm
0001692415 false Q1 --12-31 0001692415 2023-01-01 2023-03-31 0001692415 2023-05-10 0001692415 2023-03-31 0001692415 2022-12-31 0001692415 2022-01-01 2022-03-31 0001692415 2021-12-31 0001692415 2022-03-31 0001692415 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001692415 us-gaap:CommonStockMember 2022-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001692415 us-gaap:RetainedEarningsMember 2022-12-31 0001692415 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001692415 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001692415 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001692415 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001692415 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2023-03-31 0001692415 us-gaap:CommonStockMember 2023-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001692415 us-gaap:RetainedEarningsMember 2023-03-31 0001692415 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-03-31 0001692415 CODX:CustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-03-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:ThreeCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:FourCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-03-31 0001692415 CODX:OneCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001692415 CODX:CustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-03-31 0001692415 CODX:CustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001692415 us-gaap:CashMember 2023-03-31 0001692415 us-gaap:CashMember 2023-01-01 2023-03-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-03-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-03-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0001692415 us-gaap:CashMember 2022-12-31 0001692415 us-gaap:CashMember 2022-01-01 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 2022-01-01 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-03-31 0001692415 us-gaap:NoncompeteAgreementsMember 2023-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2023-03-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2023-03-31 0001692415 CODX:MeasurementInputStrikePriceMember 2022-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001692415 country:US 2023-01-01 2023-03-31 0001692415 country:US 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember 2023-01-01 2023-03-31 0001692415 CODX:RestOfWorldMember 2022-01-01 2022-03-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001692415 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2022-08-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2023-03-31 0001692415 CODX:StockOptionsMember 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001692415 us-gaap:WarrantMember 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001692415 CODX:CostOfSaleMember 2023-01-01 2023-03-31 0001692415 CODX:CostOfSaleMember 2022-01-01 2022-03-31 0001692415 CODX:SalesAndMarketingMember 2023-01-01 2023-03-31 0001692415 CODX:SalesAndMarketingMember 2022-01-01 2022-03-31 0001692415 CODX:GeneralAndAdministrativeMember 2023-01-01 2023-03-31 0001692415 CODX:GeneralAndAdministrativeMember 2022-01-01 2022-03-31 0001692415 CODX:ResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001692415 CODX:ResearchAndDevelopmentMember 2022-01-01 2022-03-31 0001692415 CODX:LeaseAmendmentMember 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File No. 001-38148

 

CO-DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Utah   46-2609396
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification Number)

 

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

 

(801) 438-1036

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CODX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

As of May 10, 2023, there were 30,263,536 shares of common stock, par value $0.001 per share, outstanding.

 

 

 

 
 

  

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

 

TABLE OF CONTENTS

 

PART I FINANCIAL INFORMATION:  
     
Item 1. Financial Statements (unaudited): 3
     
  Consolidated Balance Sheets 3
     
  Consolidated Statements of Operations 4
     
  Consolidated Statements of Cash Flows 5
     
  Consolidated Statements of Stockholders’ Equity 6
     
  Notes to Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 23
     
Item 4. Controls and Procedures 23
     
PART II OTHER INFORMATION:  
     
Item 1. Legal Proceedings 24
     
Item 1A. Risk Factors 24
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
     
Item 3. Defaults Upon Senior Securities 24
     
Item 4. Mine Safety Disclosures 24
     
Item 5. Other Information 24
     
Item 6. Exhibits 25
     
  Signatures 26

 

2
 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

         
   March 31, 2023   December 31, 2022 
Assets          
Current assets          
Cash and cash equivalents  $6,359,380   $22,973,803 
Marketable investment securities   68,920,535    58,289,066 
Accounts receivable, net   2,702,196    3,453,723 
Inventory, net   5,294,653    5,310,473 
Income taxes receivable   1,695,480    1,870,419 
Prepaid expenses and other current assets   913,175    761,187 
Note receivable   37,500    75,000 
Total current assets   85,922,919    92,733,671 
Property and equipment, net   2,510,083    2,539,483 
Operating lease right-of-use asset   952,176    372,115 
Intangible assets, net   26,661,667    26,768,333 
Investment in joint venture   950,001    672,679 
Total assets  $116,996,846   $123,086,281 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $829,819   $952,296 
Accrued expenses, current   1,492,611    934,447 
Operating lease liability, current   277,290    297,209 
Contingent consideration liabilities, current   992,229    1,689,471 
Deferred revenue   18,120    - 
Total current liabilities   3,610,069    3,873,423 
Long-term liabilities          
Income taxes payable   1,193,080    1,181,284 
Deferred tax liability   203,335    2,417,987 
Operating lease liability   658,137    50,708 
Contingent consideration liabilities   702,455    1,042,885 
Total long-term liabilities   2,757,007    4,692,864 
Total liabilities   6,367,076    8,566,287 
Commitments and contingencies (Note 10)   -    - 
Stockholders’ equity          
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively   -    - 
Common stock, $0.001 par value; 100,000,000 shares authorized; 34,823,015 shares issued and 30,632,345 shares outstanding as of March 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022   34,823    34,754 
Treasury stock, at cost; 4,190,670 and 3,881,658 shares held as of March 31, 2023 and December 31, 2022, respectively   (14,694,062)   (14,211,866)
Additional paid-in capital   90,641,608    88,472,935 
Accumulated other comprehensive income   471,761    293,140 
Accumulated earnings   34,175,640    39,931,031 
Total stockholders’ equity   110,629,770    114,519,994 
Total liabilities and stockholders’ equity  $116,996,846   $123,086,281 

 

See accompanying notes to unaudited consolidated financial statements

 

3
 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

 

         
   Three Months Ended March 31, 
   2023   2022 
Revenue  $601,957   $22,699,044 
Cost of revenue   502,241    3,281,951 
Gross profit   99,716    19,417,093 
Operating expenses          
Sales and marketing   1,706,331    2,652,148 
General and administrative   3,013,965    2,922,195 
Research and development   5,014,060    3,771,327 
Depreciation and amortization   316,010    247,264 
Total operating expenses   10,050,366    9,592,934 
Income (loss) from operations   (9,950,650)   9,824,159 
Other income          
Interest income   202,372    11,393 
Realized gain on investments   418,082    - 
(Loss) on disposition of assets   -    (93,421)
Gain on remeasurement of acquisition contingencies   1,037,672    3,379,890 
Gain (loss) on equity method investment in joint venture   277,322    (21,339)
Total other income   1,935,448    3,276,523 
Income (loss) before income taxes   (8,015,202)   13,100,682 
Income tax provision (benefit)   (2,259,811)   1,386,087 
Net income (loss)  $(5,755,391)  $11,714,595 
Other comprehensive income          
Change in net unrealized gains on marketable securities, net of tax  $178,621   $- 
Total other comprehensive income  $178,621   $- 
Comprehensive income (loss)  $(5,576,770)  $11,714,595 
           
Earnings per common share:          
Basic  $(0.20)  $0.35 
Diluted  $(0.20)  $0.34 
Weighted average shares outstanding:          
Basic   29,483,540    33,935,570 
Diluted   29,483,540    34,711,476 

 

See accompanying notes to unaudited consolidated financial statements

 

4
 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

         
   Three Months Ended March 31, 
   2023   2022 
Cash flows from operating activities          
Net (loss) income  $(5,755,391)  $11,714,595 
Adjustments to reconcile net income to cash (used in) provided by operating activities:          
Depreciation and amortization   316,010    247,264 
Stock-based compensation expense   2,168,742    1,375,097 
Change in fair value of acquisition contingencies   (1,037,672)   (3,379,890)
Non-cash lease expense   7,449    8,762 
(Gain) loss from equity method investment   (277,322)   21,339 
Loss on disposition of assets   -    93,421 
Deferred income taxes   (2,214,652)   (1,359,716)
Bad debt expense   (114,133)   47,862 
Changes in assets and liabilities:          
Accounts receivable   865,660    (871,083)
Prepaid expenses   60,451    1,042,932 
Inventory   15,821    (3,088,944)
Deferred revenue   18,120    (150,000)
Income taxes payable   11,796    2,745,803 
Accounts payable, accrued expenses and other liabilities   435,686    (641,604)
Net cash (used in) provided by operating activities   (5,499,435)   7,805,838 
Cash flows from investing activities          
Purchases of property and equipment   (179,944)   (396,600)
Proceeds from maturities of marketable investment securities   30,539,621    1,255,266 
Purchases of marketable securities   (40,992,469)   - 
Net cash (used in) provided by investing activities   (10,632,792)   858,666 
Cash flows from financing activities          
Proceeds from exercise of options and warrants   -    150,001 
Repurchases of common stock   (482,196)   - 
Net cash (used in) provided by financing activities   (482,196)   150,001 
Net (decrease) increase in cash and cash equivalents   (16,614,423)   8,814,505 
Cash and cash equivalents at beginning of period   22,973,803    88,607,234 
Cash and cash equivalents at end of period  $6,359,380   $97,421,739 
Supplemental disclosure of cash flow information          
Interest paid  $-   $- 
Income taxes paid  $29,500   $- 
Supplemental disclosure of non-cash investing and financing transactions          
Inventory moved to property, plant and equipment  $-   $192,056 
Right-of-use assets obtained in exchange for new operating lease liabilities  $657,150   $681,327 

 

See accompanying notes to unaudited consolidated financial statements

 

5
 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

 

                                     
   Convertible Preferred Stock   Common Stock   Treasury   Additional Paid-in   Accumulated Other Comprehensive   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Stock   Capital   Income   Earnings   Equity 
Balance as of December 31, 2022        -   $       -    34,754,265   $34,754   $(14,211,866)  $88,472,935   $293,140   $39,931,031   $114,519,994 
Stock-based compensation   -    -    68,750    69    -    2,168,673    -    -    2,168,742 
Repurchases of common stock   -    -    -    -    (482,196)   -    -    -    (482,196)
Other comprehensive income, net of tax   -    -    -    -    -    -    178,621    -    178,621 
Net loss   -    -    -    -    -    -    -    (5,755,391)   (5,755,391)
Balance as of March 31, 2023   -   $-    34,823,015   $34,823   $(14,694,062)  $90,641,608   $471,761   $34,175,640   $110,629,770 

 

   Convertible Preferred Stock   Common Stock   Treasury   Additional Paid-in   Accumulated Other Comprehensive   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Stock   Capital   Income   Earnings   Equity 
Balance as of December 31, 2021         -   $        -    33,819,862   $33,820   $       -   $80,271,999   $              -   $54,169,279   $134,475,100 
Common stock issued for option exercises   -    -    45,456    45    -    49,956    -    -    50,001 
Common stock issued for warrant exercises   -    -    50,000    50    -    99,950    -         100,000 
Stock-based compensation   -    -    68,750    69    -    1,375,028    -    -    1,375,097 
Net income   -    -    -    -    -    -    -    11,714,595    11,714,595 
Balance as of March 31, 2022   -   $-    33,984,068   $33,984   $-   $81,796,933   $-   $65,883,874   $147,714,793 

 

See accompanying notes to unaudited consolidated financial statements

 

6
 

 

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR device and proprietary test cups (the “Co-Dx PCR Home™ platform”) that have been designed to bring affordable, reliable polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings. This platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. There is no guarantee the Co-Dx PCR Home platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform. 

 

Unaudited Consolidated Financial Statements

 

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed on March 16, 2023.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Note 2 – Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the condensed consolidated statements of operations and comprehensive income.

 

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

 

7
 

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2023, total accounts receivable was $5,686,589 with an allowance for uncollectable accounts of $2,984,393 resulting in a net amount of $2,702,196. At December 31, 2022, total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2023, the Company had $5,294,653 in inventory, comprised of $1,081,540 of finished goods, and $4,213,113 of raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Intangible Assets

 

Indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

 

Long-lived Assets

 

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 

Leases

 

The Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

 

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

 

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

8
 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

Research and Development

 

Research and development costs are expensed when incurred. For the three months ended March 31, 2023, the Company expensed $5,014,060 of research and development costs, respectively. For the three months ended March 31, 2022, the Company expensed $3,771,327.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Comprehensive Income

 

Comprehensive income is comprised of unrealized gains and losses on marketable securities, net of income taxes.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2023. Two customers accounted for approximately 44% of total revenue for the three months ended March 31, 2023. Three customers together accounted for approximately 54% of total revenue for the three months ended March 31, 2022.

 

Four customers accounted for more than 10% of accounts receivable at March 31, 2023 and one customer accounted for more than 10% of accounts receivable at December 31, 2022. These customers together accounted for approximately 82% and 37% of accounts receivable at March 31, 2023 and December 31, 2022, respectively.

 

9
 

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

Note 3 - Cash, Cash Equivalents, and Financial Instruments

 

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 

   March 31, 2023 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $6,089,090   $        -   $-   $6,089,090   $6,089,090   $- 
Level 1:                              
Money market funds   270,290    -    -    270,290    270,290    - 
Subtotal   270,290    -    -    270,290    270,290    - 
Level 2:                              
U.S. treasury securities   68,294,247    -    626,288    68,920,535    -    68,920,535 
Subtotal   68,294,247    -    626,288    68,920,535    -    68,920,535 
Total  $74,653,627   $-   $626,288   $75,279,915   $6,359,380   $68,920,535 

 

   December 31, 2022 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $12,834,444   $       -   $-   $12,834,444   $12,834,444   $- 
Level 1:                              
Money market funds   146,359    -    -    146,359    146,359    - 
Subtotal   146,359    -    -    146,359    146,359    - 
Level 2:                              
U.S. treasury securities   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Subtotal   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Total  $80,873,628   $-   $389,241   $81,262,869   $22,973,803   $58,289,066 

 

Marketable investment securities held as of March 31, 2023 mature over the next 12 months.

 

10
 

 

Note 4 – Intangible Assets, Net

 

Intangible assets, net consisted of the following:

 

   March 31, 2023
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (533,333)   560,667 
Total intangible assets     $27,195,000   $(533,333)  $26,661,667 

 

   December 31, 2022
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (426,667)   667,333 
Total intangible assets     $27,195,000   $(426,667)  $26,768,333 

 

(1) Based on weighted-average useful life established as of the acquisition date.

 

11
 

 

The expected future annual amortization expense of the Company’s intangible assets held as of March 31, 2023 is as follows:

 

Year Ending December 31,  Amortization Expense 
2023   258,003 
2024   302,664 
Total  $560,667 

 

Note 5 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

12
 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, by level within the fair value hierarchy:

 

                 
   March 31, 2023 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Cash equivalents  $-   $298,605   $-   $298,605 
Marketable securities (U.S. treasury bills and notes)   -    68,920,535    -    68,920,535 
Total assets measured at fair value  $-   $69,219,140   $-   $69,219,140 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $1,467,753   $1,467,753 
Contingent consideration - warrants   -    -    226,931    226,931 
Total liabilities measured at fair value  $-   $-   $1,694,684   $1,694,684 

 

                 
   December 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Cash equivalents  $-   $10,179,667   $-   $10,179,667 
Marketable securities (U.S. treasury bills and notes)   -    58,289,066    -    58,289,066 
Total assets measured at fair value  $-   $68,468,733   $-   $68,468,733 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $2,499,147   $2,499,147 
Contingent consideration - warrants   -    -    233,209    233,209 
Total liabilities measured at fair value  $-   $-   $2,732,356   $2,732,356 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of U.S. treasury bills and notes as of March 31, 2023 and December 31, 2022.

 

In connection with the acquisitions of IdMo and ACI on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2022  $2,732,356 
Change in fair value of contingent consideration issued for business acquisitions   (1,037,672)
Fair value as of March 31, 2023  $1,694,684 

 

13
 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   March 31, 2023   December 31, 2022 
Stock price  $1.48   $2.52 
Strike price  $9.13   $9.13 
Volatility   117.00%   75.00%
Risk-free rate   3.70%   4.10%
Expected term   3.8    4.0 

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

 

Note 6 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Three Months Ended March 31, 
   2023   2022 
United States  $393,154   $14,218,398 
Rest of World   208,803    8,480,646 
Total  $601,957   $22,699,044 
Percentage of revenue by area:          
United States   65%   63%
Rest of World   35%   37%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 were as follows:

 

Balance as of December 31, 2022  $- 
Increase due to prepayments from customers   18,120 
Balance as of March 31, 2023  $18,120 

 

14
 

 

Note 7 – Earnings Per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2023 and 2022, respectively:

 

   2023   2022 
   Three Months Ended March 31, 
   2023   2022 
Numerator        
Net income, as reported  $(5,755,391)  $11,714,595 
           
Denominator          
Weighted average shares, basic   29,483,540    33,935,570 
Dilutive effect of stock options, warrants and RSUs   -    775,906 
Shares used to compute diluted earnings per share   29,483,540    34,711,476 
           
Basic earnings per share  $(0.20)  $0.35 
Diluted earnings per share  $(0.20)  $0.34 

 

For the three months ended March 31, 2022, potentially dilutive securities of 1,271,304 were excluded from the calculation because their effect would have been anti-dilutive. The computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022, respectively, also excludes the approximately 1.4 million shares of common stock and approximately 465,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

 

As a result of incurring a net loss for the three months ended March 31, 2023, no potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of March 31, 2023, consisting of: (i) 2,732,517 restricted stock units and (ii) 120,445 options.

 

Note 8 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022, the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock. The number of awards available for issuance under the Incentive Plan was 5,518,290 at March 31, 2023.

 

Stock Options

 

The following table summarizes option activity during the three months ended March 31, 2023:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2022   1,040,572   $2.19   $1.37    5.88 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at March 31, 2023   1,040,572   $2.19   $1.37    5.64 
                     
Exercisable at March 31, 2023   1,040,572   $2.19   $1.37    5.64 

 

The aggregate intrinsic value of outstanding options at March 31, 2023 was approximately $0.3 million.

 

15
 

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. As of March 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2023:

 

  

Number of

RSUs

   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2022   2,426,725   $6.95 
Granted   692,500    2.82 
Vested   (68,750)   10.23 
Forfeited/Cancelled   -    - 
Unvested at March 31, 2023   3,050,475   $5.94 

 

As of March 31, 2023, there was approximately $14.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.1 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the three months ended March 31, 2023:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2022   485,000   $8.81   $2.43    4.0 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at March 31, 2023   485,000   $8.81   $1.09    3.8 

 

16
 

 

There were no warrants exercised during the three months ended March 31, 2023. The intrinsic value of warrants exercised during the three months ended March 31, 2022 was approximately $0.3 million. The aggregate intrinsic value of outstanding warrants at March 31, 2023 was approximately $0.1 million.

 

The total number of warrants exercisable at March 31, 2023 is 20,000. The ability to exercise the approximately 465,000 warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense as follows:

 

         
   Three Months Ended March 31, 
   2023   2022 

Cost of sales

  $

12,008

   $

12,327

 

Sales and marketing

   

529,117

    

388,017

 
General and administrative   

1,192,214

    

765,199

 
Research and development   

435,403

    

209,554

 
Total stock-based compensation expense  $2,168,742   $1,375,097 

 

Note 9 – Income Taxes

 

For the three months ended March 31, 2023, the Company recognized a benefit from income taxes of $2,259,811, representing an effective tax rate of 28.2%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2022, the Company recognized expense from income taxes of $1,386,087.

 

Note 10 – Commitments and Contingencies

 

Lease Obligations

 

The Company leases office space under a non-cancellable operating lease and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed. During the three months ended March 31, 2023, this lease was amended to extend the lease term. As a result of this amendment, the Company recognized an additional operating lease liability and corresponding operating right-of-use asset of $657,150.

 

For the three months ended March 31, 2023, components of lease expense are summarized as follows:

 

   Three Months Ended March 31, 2023 
Operating lease costs  $87,607 
Short-term lease costs   108,678 
Total lease costs  $196,285 

 

Short-term lease costs under month-to-month lease agreements are paid to related parties.

 

As of March 31, 2023, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2023  $245,226 
2024   353,919 
2025   368,291 
2026   61,680 
2027   - 
Thereafter   - 
Total lease payments   1,029,116 
Less: imputed interest   93,689 
Present value of operating lease liabilities   935,427 
Less: current portion   277,290 
Long-term portion  $658,137 

 

17
 

 

Other information related to operating leases was as follows:

 

  

Three Months Ended

March 31, 2023

 
Cash paid for operating leases included in operating cash flows  $188,835 
Remaining lease term of operating leases   3 years  
Discount rate of operating leases   6.7%

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two commercial litigation lawsuits in which plaintiffs are claiming they are owned certain remuneration based on alleged agreements with the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 

Note 11 – Share Repurchase Program

 

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:

 

   Three Months Ended 
   March 31, 2023 
Balance, beginning of period   3,881,658 
Repurchases of common stock   309,012 
Balance, end of period   4,190,670 

 

Note 12 – Subsequent Events

 

None.

 

18
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time, and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 16, 2023, and the audited financial statements and notes included therein.

 

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report to conform our statements to actual results or changed expectations.

 

You are advised, however, to consult any further disclosures we make on related subjects in our periodic and current reports filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties.

 

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

 

● the results of clinical trials and the regulatory approval process;
   
● market acceptance of any products that may be approved for commercialization;
   
● our ability to protect our intellectual property rights;
   
● the impact of any infringement actions or other litigation brought against us;
   
● competition from other providers and products;
   
● our ability to develop and commercialize new and improved products and services;
   
● changes in government regulation;
   
● and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

 

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

As used in this Quarterly Report, the terms “we”, “us”, “our”, and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated.

 

Executive Overview

 

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying unaudited financial statements and notes thereto included elsewhere in this report. The information contained in this discussion is subject to a number of risks and uncertainties. We urge you to review carefully the section of this report entitled “Cautionary Note Regarding Forward-Looking Statements” for a summary of the risks and uncertainties associated with an investment in our securities.

 

19
 

 

Business Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR device and proprietary test cups (the “Co-Dx PCR Home platform”) that have been designed to bring affordable, reliable polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings. This platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. There is no guarantee that our Co-Dx PCR Home platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform.

 

Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification: the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA.

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own platform, we believe we will be able to accomplish this faster and more economically than some competitors, allowing for significant margins while still positioning ourselves as a low-cost provider of molecular diagnostics and screening services.

 

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

 

Our scientists use the complex mathematics of DNA/RNA PCR test design to engineer and optimize PCR tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Brent Satterfield, our founder, developed the intellectual property we use in our business, consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represent a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

 

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended. Verification involves a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

We may either sell or lease the MDx Device to labs and diagnostic centers, through sale or lease agreements, and sell the reagents that comprise our proprietary tests to those laboratories and testing facilities.

 

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and/or in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. In the United States, we obtained Emergency Use Authorization (“EUA”) for our Logix Smart™ COVID-19 detection test from the Food and Drug Administration, or FDA, and we sell that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries.

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describes any type of genetic trait, which creates several significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

20
 

 

RESULTS OF OPERATIONS

 

The Three Months Ended March 31, 2023 Compared to the Three Months ended March 31, 2022

 

Revenues

 

For the three months ended March 31, 2023, we generated revenues of $601,957, compared to revenues of $22,699,044 for the three months ended March 31, 2022. The decrease in revenue of $22,097,087 was primarily due to lower sales of our Logix Smart COVID-19 test developed in response to the COVID-19 pandemic.

 

Cost of Revenues

 

We recorded cost of revenues of $502,241 for the three months ended March 31, 2023, compared to $3,281,951 for the three months ended March 31, 2022. The decrease in revenues combined with a larger percentage of fixed product production costs, as well as costs related to expired inventory, resulted in a lower cost of revenues and lower gross margin percentage.

 

Expenses

 

We incurred total operating expenses of $10,050,366 for the three months ended March 31, 2023, compared to total operating expenses of $9,592,934 for the three months ended March 31, 2022. The increase in operating expenses was primarily due to increased personnel expenses, including stock-compensation expense, and additional investment in research and development. These increases were partially offset by decreased expenses experienced in conjunction with our decrease in revenues, such as third party sales commissions reflected in sales and marketing and variable compensation.

 

Our sales and marketing expenses for the three months ended March 31, 2023 were $1,706,331, compared to $2,652,148 for the three months ended March 31, 2022. The decrease was primarily a result of decreased variable compensation, such as bonuses and commissions, and decreased third-party sales commissions, partially offset by increased stock-based compensation expense.

 

General and administrative expenses increased slightly from $2,922,195 for the three months ended March 31, 2022 to $3,013,965 for the three months ended March 31, 2023. The increase in general and administrative expenses was primarily due to increased insurance expense and professional, legal, and advisory fees, as well as increased stock-based compensation expense, partially offset by decreased variable compensation expense.

 

Our research and development expenses increased from $3,771,327 for the three months ended March 31, 2022 to $5,014,060 for the three months ended March 31, 2023. The primary increase in expenses was a result of increases in personnel related expenses, increases in materials and supplies expenses related to Co-Dx PCR Home platform development, and increased stock-based compensation expense.

 

21
 

 

Other Income (expense)

 

For the three months ended March 31, 2023 we had total other income of $1,935,448, compared to total other income of $3,276,523 for the three months ended March 31, 2022. The primary components of other income include a change in the fair value of contingent consideration liabilities recorded in conjunction with the acquisitions of IdMo and ACI and gains realized from investments in marketable securities.

 

Net Income (loss)

 

We realized a net loss for the three months ended March 31, 2023 of $5,755,391, compared with net income for the three months ended March 31, 2022 of $11,714,595. The decrease in net income was primarily the result of a decrease in revenues, combined with an increase of operating expenses, as well as changes in the fair value of acquisition contingencies. Additionally, we recorded an income tax benefit of $2,259,811 for the three months ended March 31, 2023, compared to income tax expense of $1,386,087 for the three months ended March 31, 2022.

 

Liquidity and Capital Resources

 

At March 31, 2023, we had cash and cash equivalents of $6,359,380. Additionally, we had $68,920,535 of marketable investment securities that could readily be converted into cash if needed. Additionally, our total current assets of March 31, 2023, were $85,922,919 compared to total current liabilities of $3,610,069.

 

Net cash used in operating activities during the three months ended March 31, 2023 was $5,499,435, compared to cash provided by operating activities of $7,805,838 for the three months ended March 31, 2022. The decrease in cash from operating activities was primarily due to decreased revenues and the impact of non-cash items.

 

We used $10,632,792 of cash in investing activities during the three months ended March 31, 2023, primarily from purchases of marketable securities, offset by maturities of marketable investments, compared to cash from investing activities of $858,666 during the three months ended March 31, 2022.

 

Net cash used in financing activities was $482,196 for the three months ended March 31, 2023, compared to net cash provided by financing activities of $150,001 for the same period in the prior year. This decrease is due to the repurchase of outstanding common shares during the first quarter.

 

Since commencing sales of our Logix Smart COVID-19 test in March 2020, we have used cash generated from those sales to fund the increase in our inventories and receivables and pay our operating expenses. We have increased our work force primarily in the area of research and development to develop the Co-Dx PCR Home platform and complete development of additional tests to enable us to use our distributor network to sell other products throughout the world and remain profitable in the future. In March 2022 our board of directors authorized the repurchase of up to $30.0 million of the company’s outstanding common stock. We have no obligation to repurchase any shares under the repurchase program and may suspend or discontinue it at any time without prior notice. As of March 31, 2023 we have repurchased 4,190,670 outstanding common shares under the repurchase program for a total of $14.7 million.

 

Additionally, in March 2023, we filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) with the SEC registering the sale, from time-to-time of up to $150 million of our securities. In connection with the Shelf Registration Statement, we filed an equity distribution agreement prospectus covering the offering, issuance and sale of up to a maximum of $50 million shares of our common stock that may be issued and sold under an equity distribution agreement with Piper Sandler & Co. We are under no obligation to sell any securities under the Shelf Registration Statement or the equity distribution agreement with Piper Sandler & Co.

 

We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities.

 

If needed, we expect additional investment capital to come from (i) additional issuances of our common stock with existing and new investors or (ii) the private placement of other securities with investors similar to those that have provided funding in the past. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.

 

22
 

 

The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls were effective.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2023, that have materially affected or, are reasonably likely to materially affect, our internal control over financial reporting.

 

23
 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There have been no material developments to the legal proceedings previously disclosed under Part I. Item 3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

Item 1A. Risk Factors.

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Dividends

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our Board of Directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future.

 

Pursuant to Section 16-10a-640 of the Utah Revised Business Corporation Act, no distribution may be made if, after giving it effect:

 

  (a) the corporation would not be able to pay its debts as they become due in the usual course of business; or
     
  (b) the corporation’s total assets would be less than the sum of its total liabilities plus, unless the articles of incorporation permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution.

 

Share Repurchase Program

 

Issuer Purchase of Equity Securities
Period  (a) Total number of shares purchased (1)   (b) Average price paid per share (1)   (c ) Total number of shares purchased as part of publicly announced plans or programs (1)   (d) Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1) 
01/01/23 – 01/31/23   -   $-    -   $15,788,134 
02/01/23 – 02/28/23   -   $-    -   $15,788,134 
03/01/23 – 03/31/23   309,012   $1.56    309,012   $15,305,938 
                     
Total   309,012   $1.56    309,012   $15,305,938 

 

  (1) In March 2022 the company announced that its board of directors authorized the repurchase of up to $30.0 million of the company’s outstanding common stock. The extent to which the company repurchases its shares, and the timing of such repurchases, will depend upon a variety of factors, including trading volume, market conditions, legal requirements, business conditions and other factors. The repurchase program may be discontinued at any time, and the program does not obligate the company to acquire any specific number of shares of its common stock.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

24
 

 

Item 6. Exhibits

 

Exhibit Index

 

(a) Exhibits

 

Exhibit   Number Description
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File

 

* Filed herewith.

 

25
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.

 

Date: May 11, 2023 By: /s/ Dwight H. Egan
  Name: Dwight H. Egan
  Title: Chief Executive Officer, President and Principal Executive Officer
     
Date: May 11, 2023 By: /s/ Brian Brown
  Name:  Brian Brown
  Title: Chief Financial Officer and Principal Financial and Accounting Officer

 

26

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13a-14 OF THE EXCHANGE ACT OF 1934

 

I, Dwight H. Egan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepting accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 11, 2023 By: /s/ Dwight H. Egan
    Dwight H. Egan
    Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13a-14 OF THE EXCHANGE ACT OF 1934

 

I, Brian Brown, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepting accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 11, 2023 By: /s/ Brian Brown
    Brian Brown
    Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Dwight H. Egan, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 11, 2023 By: /s/ Dwight H. Egan
    Dwight H. Egan
    Chief Executive Officer, President and Principal Executive Officer

 

 

 

 

 EX-32.2 5 ex32-2.htm

  

EXHIBIT 32.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Brian Brown, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 11, 2023 By: /s/ Brian Brown
    Brian Brown
    Chief Financial Officer and Principal Financial and Accounting Officer

 

 

  

 EX-101.SCH 6 codx-20230331.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Overview and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Cash, Cash Equivalents, and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Share Repurchase Program link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Cash, Cash Equivalents, and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Share Repurchase Program (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Cash,Cash Equivalents and Marketable Investment Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Changes in the Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Summary of Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Other Information Related to Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Share Repurchase Program (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 codx-20230331_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 codx-20230331_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 codx-20230331_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Preferred Stock [Member] Class of Stock [Axis] Convertible Preferred Stock [Member] Common Stock [Member] Treasury Stock, Common [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Customer [Axis] Customers [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Two Customers Together [Member] Revenue Benchmark [Member] Three Customers Together [Member] Four Customers [Member] One Customers [Member] Customers Together [Member] Cash and Cash Equivalents [Axis] Cash [Member] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] US Treasury Securities [Member] Fair Value, Inputs, Level 2 [Member] Finite-Lived Intangible Assets by Major Class [Axis] In Process Research and Development [Member] Noncompete Agreements [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input Strike Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Geographical [Axis] UNITED STATES Rest of World [Member] Geographic Concentration Risk [Member] Warrant [Member] Antidilutive Securities [Axis] Restricted Stock Units (RSUs) [Member] Share-Based Payment Arrangement, Option [Member] Plan Name [Axis] 2015 Long Term Incentive Plan [Member] Award Type [Axis] Stock Options [Member] Cost Of Sale [Member] Sales And Marketing [Member] General And Administrative [Member] Research And Development [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Lease Amendment [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Marketable investment securities Accounts receivable, net Inventory, net Income taxes receivable Prepaid expenses and other current assets Note receivable Total current assets Property and equipment, net Operating lease right-of-use asset Intangible assets, net Investment in joint venture Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued expenses, current Operating lease liability, current Contingent consideration liabilities, current Deferred revenue Total current liabilities Long-term liabilities Income taxes payable Deferred tax liability Operating lease liability Contingent consideration liabilities Total long-term liabilities Total liabilities Commitments and contingencies (Note 10) Stockholders’ equity Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively Common stock, $0.001 par value; 100,000,000 shares authorized; 34,823,015 shares issued and 30,632,345 shares outstanding as of March 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022 Treasury stock, at cost; 4,190,670 and 3,881,658 shares held as of March 31, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated other comprehensive income Accumulated earnings Total stockholders’ equity Total liabilities and stockholders’ equity Convertible preferred stock, par value Convertible preferred stock , shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Sales and marketing General and administrative Research and development Depreciation and amortization Total operating expenses Income (loss) from operations Other income Interest income Realized gain on investments (Loss) on disposition of assets Gain on remeasurement of acquisition contingencies Gain (loss) on equity method investment in joint venture Total other income Income (loss) before income taxes Income tax provision (benefit) Net income (loss) Other comprehensive income Change in net unrealized gains on marketable securities, net of tax Total other comprehensive income Comprehensive income (loss) Earnings per common share: Basic Diluted Weighted average shares outstanding: Basic Diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net (loss) income Adjustments to reconcile net income to cash (used in) provided by operating activities: Depreciation and amortization Stock-based compensation expense Change in fair value of acquisition contingencies Non-cash lease expense (Gain) loss from equity method investment Loss on disposition of assets Deferred income taxes Bad debt expense Changes in assets and liabilities: Accounts receivable Prepaid expenses Inventory Deferred revenue Income taxes payable Accounts payable, accrued expenses and other liabilities Net cash (used in) provided by operating activities Cash flows from investing activities Purchases of property and equipment Proceeds from maturities of marketable investment securities Purchases of marketable securities Net cash (used in) provided by investing activities Cash flows from financing activities Proceeds from exercise of options and warrants Repurchases of common stock Net cash (used in) provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Interest paid Income taxes paid Supplemental disclosure of non-cash investing and financing transactions Inventory moved to property, plant and equipment Right-of-use assets obtained in exchange for new operating lease liabilities Statement [Table] Statement [Line Items] Balance Balance, shares Stock-based compensation Stock-based compensation expense, shares Repurchases of common stock Other comprehensive income, net of tax Net income (loss) Common stock issued for option exercises Common stock issued for option exercises, shares Common stock issued for warrant exercises Common stock issued for warrant exercises, shares Balance Balance, shares Accounting Policies [Abstract] Overview and Basis of Presentation Summary of Significant Accounting Policies Cash and Cash Equivalents [Abstract] Cash, Cash Equivalents, and Financial Instruments Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, Net Fair Value Disclosures [Abstract] Fair Value Measurements Revenue from Contract with Customer [Abstract] Revenue Earnings Per Share [Abstract] Earnings Per Share Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Share Repurchase Program Subsequent Events [Abstract] Subsequent Events Reclassifications Cash and Cash Equivalents Marketable Investment Securities Accounts Receivable Equity-Method Investments Inventory Intangible Assets Long-lived Assets Business Combinations Leases Revenue Recognition Deferred Revenue Research and Development Stock-based Compensation Income Taxes Net Income per Share Comprehensive Income Concentrations Risk and Significant Customers Recently Issued Accounting Standards Schedule of Cash,Cash Equivalents and Marketable Investment Securities Schedule of Intangible Assets, Net Schedule of Future Amortization Expense Schedule of Fair Value Assets and Liabilities Schedule of Changes in the Fair Value Measurement Schedule of Contingent Consideration Common Stock and Warrants Summary of Revenue by Geographic Area Schedule of Deferred Revenue Schedule of Basic and Diluted Earnings Per Share Schedule of Option Activity Schedule of Outstanding Restricted Stock Units and Related Activity Schedule of Warrant Activity Schedule of Recognized Stock-based Compensation Expense Schedule of Lease Expense Schedule of Maturities on Company Lease Liabilities Schedule of Other Information Related to Operating Lease Schedule of Treasury Stock Schedule of Product Information [Table] Product Information [Line Items] Accounts receivable, before allowance for credit loss, current Uncollectable accounts Accounts receivable, after allowance for credit loss, current Inventory, finished goods, gross Inventory, raw materials, gross Research and development expense Concentration risk percentage Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Line Items] Adjusted Cost Allowance for Credit Losses Total Unrealized Gains / (Losses) Fair Value Cash and Cash Equivalents Marketable Securities Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful lives in years, term Intangible assets, gross Less accumulated amortization Estimated useful lives in years 2023 2024 Total Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents Marketable securities (U.S. treasury bills and notes) Total assets measured at fair value Contingent consideration - common stock Contingent consideration - warrants Total liabilities measured at fair value Fair value as of December 31, 2022 Change in fair value of contingent consideration issued for business acquisitions Fair value as of March 31, 2023 Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants measurement input Expected term Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue Percentage of revenue Deferred revenue, beginning balance Increase due to prepayments from customers Deferred revenue, ending balance Net income, as reported Weighted average shares, basic Dilutive effect of stock options, warrants and RSUs Shares used to compute diluted earnings per share Basic earnings per share Diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities excluded from computation of diluted earnings per share Number of Options Outstanding, Beginning Weighted Average Exercise Price Outstanding, Beginning Weighted Average Fair Value Outstanding, Beginning Weighted-average Remaining Contractual Life (years) Outstanding, Beginning Number of Options Outstanding, Granted Weighted Average Exercise Price Granted Weighted Average Fair Value Granted Number of Options Outstanding, Expired Weighted Average Exercise Price Expired Weighted Average Fair Value Expired Number of Options Outstanding, Forfeited/Cancelled Weighted Average Exercise Price Forfeited/Cancelled Weighted Average Fair Value Forfeited/Cancelled Number of Options Outstanding, Exercised Weighted Average Exercise Price Exercised Weighted Average Fair Value Exercised Number of Options Outstanding, Ending Weighted Average Exercise Price Outstanding, Ending Weighted Average Fair Value Outstanding, Ending Weighted-average Remaining Contractual Life (years) Outstanding, Ending Number of Options Exercisable Ending Weighted Average Exercise Price, Exercisable Ending Weighted Average Fair Value, Exercisable Ending Weighted-average Remaining Contractual Life (years), Exercisable Ending Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Restricted Stock Units, Outstanding Beginning Weighted Average Grant Date Fair Value, Outstanding Beginning Number of Restricted Stock Units, Granted Weighted Average Grant Date Fair Value, Granted Number of Restricted Stock Units, Vested Weighted Average Grant Date Fair Value, Vested Number of Restricted Stock Units, Forfeited/Cancelled Weighted Average Grant Date Fair Value, Forfeited/Cancelled Number of Restricted Stock Units, Outstanding Ending Weighted Average Grant Date Fair Value, Outstanding Ending Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average fair value, Beginning Weighted-average Remaining Contractual Life (Years) Outstanding Number of Warrants Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Fair Value, Granted Number of Warrants Outstanding, Expired Weighted Average Exercise Price, Expired Weighted Average Fair Value, Expired Number of Warrants Outstanding, Forfeited/Cancelled Weighted Average Exercise Price, Forfeited/Cancelled Weighted Average Fair Value, Forfeited/Cancelled Number of Warrants Outstanding, Exercised Weighted Average Exercise Price, Exercised Weighted Average Fair Value, Exercised Number of Warrants Outstanding, Ending Weighted Average Exercise Price, Ending Weighted Average Fair Value, Ending Weighted-average Remaining Contractual Life (Years) Outstanding Total stock-based compensation expense Number of common shares availalble for issuance Aggregate intrinsic value of options outstanding Unrecognized stock-based compensation Unrecognized stock-based compensation recognition period Intrinsic value of warrants exercised Warrants exercisable Warrants to purchase a common stock Income tax expense (benefit) Effective income tax rate reconciliation, percent Effective income tax rate reconciliation, percent Income tax expense (benefit) Operating lease costs Short-term lease costs Total lease costs 2023 2024 2025 2026 2027 Thereafter Total lease payments Less: imputed interest Present value of operating lease liabilities Less: current portion Long-term portion Cash paid for operating leases included in operating cash flows Remaining lease term of operating leases Discount rate of operating leases Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Operating lease liabilities Treasury stock, Beginning Balance Repurchases of common stock Treasury stock, Ending Balance Stock repurchase program authorized amount Taxes payable non current. Gain on remeasurement of acquisition contingencies. Noncash lease expense. Noncash or part noncash inventory moved to property plant and equipment.. Reclassifications Policy [Text [Block] Customers [Member] Two Customers Together [Member] Three Customers Together [Member] Four Customers [Member] Two Customers [Member] Customers Together [Member] Indefinite lived intangible asset useful life. Fair value of contingent consideration to common stock. Fair value of contigent consideration to warrants. Contingent considered issued for measurement period adjustments. Contingent considered issued for business acquisitions. Measurement Input Strike Price [Member] Rest of World [Member] Increase due to prepayments from customers. 2015 Long Term Incentive Plan [Member] Stock Options [Member] Weighted average exercise price, beginning. Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan. Weighted average exercise price granted. Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired. Weighted average exercise price, forfeited/cancelled. Weighted average exercise price, forfeited/cancelled. Share based compensation arrangement by share based payment award non options outstanding weighted average fair value. Weighted average fair value, beginning. Weighted average grant date fair value, granted Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Weighted average fair value, forfeited/cancelled. Weighted average fair value, exercised. Weighted-average remaining contractual life (years) outstanding, beginning. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term3. Intrinsic value of warrants exercised. Class of warrant exercisable. Schedule of Operating Lease [Table Text Block] Schedule of Treasury Stock [Table Text Block] Repurchases of common stock. One Customers [Member] Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term. Lease Amendment [Member] Assets, Current Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities Treasury Stock, Value Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Depreciation, Depletion and Amortization Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Marketable Securities Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Common Stock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding Stock Repurchased During Period, Value Revenue from Contract with Customer [Text Block] Income Tax, Policy [Policy Text Block] Finite-Lived Intangible Assets, Net Business Combination, Contingent Consideration, Liability, Noncurrent Revenue from Contract with Customer, Including Assessed Tax Contract with Customer, Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3 Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 10 codx-20230331_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
May 10, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38148  
Entity Registrant Name CO-DIAGNOSTICS, INC.  
Entity Central Index Key 0001692415  
Entity Tax Identification Number 46-2609396  
Entity Incorporation, State or Country Code UT  
Entity Address, Address Line One 2401 S. Foothill Drive  
Entity Address, Address Line Two Suite D  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84109  
City Area Code (801)  
Local Phone Number 438-1036  
Title of 12(b) Security Common Stock  
Trading Symbol CODX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   30,263,536
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 6,359,380 $ 22,973,803
Marketable investment securities 68,920,535 58,289,066
Accounts receivable, net 2,702,196 3,453,723
Inventory, net 5,294,653 5,310,473
Income taxes receivable 1,695,480 1,870,419
Prepaid expenses and other current assets 913,175 761,187
Note receivable 37,500 75,000
Total current assets 85,922,919 92,733,671
Property and equipment, net 2,510,083 2,539,483
Operating lease right-of-use asset 952,176 372,115
Intangible assets, net 26,661,667 26,768,333
Investment in joint venture 950,001 672,679
Total assets 116,996,846 123,086,281
Current liabilities    
Accounts payable 829,819 952,296
Accrued expenses, current 1,492,611 934,447
Operating lease liability, current 277,290 297,209
Contingent consideration liabilities, current 992,229 1,689,471
Deferred revenue 18,120
Total current liabilities 3,610,069 3,873,423
Long-term liabilities    
Income taxes payable 1,193,080 1,181,284
Deferred tax liability 203,335 2,417,987
Operating lease liability 658,137 50,708
Contingent consideration liabilities 702,455 1,042,885
Total long-term liabilities 2,757,007 4,692,864
Total liabilities 6,367,076 8,566,287
Commitments and contingencies (Note 10)
Stockholders’ equity    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 34,823,015 shares issued and 30,632,345 shares outstanding as of March 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022 34,823 34,754
Treasury stock, at cost; 4,190,670 and 3,881,658 shares held as of March 31, 2023 and December 31, 2022, respectively (14,694,062) (14,211,866)
Additional paid-in capital 90,641,608 88,472,935
Accumulated other comprehensive income 471,761 293,140
Accumulated earnings 34,175,640 39,931,031
Total stockholders’ equity 110,629,770 114,519,994
Total liabilities and stockholders’ equity $ 116,996,846 $ 123,086,281
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value $ 0.001 $ 0.001
Convertible preferred stock , shares authorized 5,000,000 5,000,000
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 34,823,015 34,754,265
Common stock, shares outstanding 30,632,345 30,872,607
Treasury stock, shares 4,190,670 3,881,658
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 601,957 $ 22,699,044
Cost of revenue 502,241 3,281,951
Gross profit 99,716 19,417,093
Operating expenses    
Sales and marketing 1,706,331 2,652,148
General and administrative 3,013,965 2,922,195
Research and development 5,014,060 3,771,327
Depreciation and amortization 316,010 247,264
Total operating expenses 10,050,366 9,592,934
Income (loss) from operations (9,950,650) 9,824,159
Other income    
Interest income 202,372 11,393
Realized gain on investments 418,082
(Loss) on disposition of assets (93,421)
Gain on remeasurement of acquisition contingencies 1,037,672 3,379,890
Gain (loss) on equity method investment in joint venture 277,322 (21,339)
Total other income 1,935,448 3,276,523
Income (loss) before income taxes (8,015,202) 13,100,682
Income tax provision (benefit) (2,259,811) 1,386,087
Net income (loss) (5,755,391) 11,714,595
Other comprehensive income    
Change in net unrealized gains on marketable securities, net of tax 178,621
Total other comprehensive income 178,621
Comprehensive income (loss) $ (5,576,770) $ 11,714,595
Earnings per common share:    
Basic $ (0.20) $ 0.35
Diluted $ (0.20) $ 0.34
Weighted average shares outstanding:    
Basic 29,483,540 33,935,570
Diluted 29,483,540 34,711,476
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net (loss) income $ (5,755,391) $ 11,714,595
Adjustments to reconcile net income to cash (used in) provided by operating activities:    
Depreciation and amortization 316,010 247,264
Stock-based compensation expense 2,168,742 1,375,097
Change in fair value of acquisition contingencies (1,037,672) (3,379,890)
Non-cash lease expense 7,449 8,762
(Gain) loss from equity method investment (277,322) 21,339
Loss on disposition of assets 93,421
Deferred income taxes (2,214,652) (1,359,716)
Bad debt expense (114,133) 47,862
Changes in assets and liabilities:    
Accounts receivable 865,660 (871,083)
Prepaid expenses 60,451 1,042,932
Inventory 15,821 (3,088,944)
Deferred revenue 18,120 (150,000)
Income taxes payable 11,796 2,745,803
Accounts payable, accrued expenses and other liabilities 435,686 (641,604)
Net cash (used in) provided by operating activities (5,499,435) 7,805,838
Cash flows from investing activities    
Purchases of property and equipment (179,944) (396,600)
Proceeds from maturities of marketable investment securities 30,539,621 1,255,266
Purchases of marketable securities (40,992,469)
Net cash (used in) provided by investing activities (10,632,792) 858,666
Cash flows from financing activities    
Proceeds from exercise of options and warrants 150,001
Repurchases of common stock (482,196)
Net cash (used in) provided by financing activities (482,196) 150,001
Net (decrease) increase in cash and cash equivalents (16,614,423) 8,814,505
Cash and cash equivalents at beginning of period 22,973,803 88,607,234
Cash and cash equivalents at end of period 6,359,380 97,421,739
Supplemental disclosure of cash flow information    
Interest paid
Income taxes paid 29,500
Supplemental disclosure of non-cash investing and financing transactions    
Inventory moved to property, plant and equipment 192,056
Right-of-use assets obtained in exchange for new operating lease liabilities $ 657,150 $ 681,327
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 33,820 $ 80,271,999 $ 54,169,279 $ 134,475,100
Balance, shares at Dec. 31, 2021 33,819,862          
Stock-based compensation $ 69 1,375,028 1,375,097
Stock-based compensation expense, shares   68,750          
Net income (loss) 11,714,595 11,714,595
Common stock issued for option exercises $ 45 49,956 50,001
Common stock issued for option exercises, shares   45,456          
Common stock issued for warrant exercises $ 50 99,950   100,000
Common stock issued for warrant exercises, shares   50,000          
Balance at Mar. 31, 2022 $ 33,984 81,796,933 65,883,874 147,714,793
Balance, shares at Mar. 31, 2022 33,984,068          
Balance at Dec. 31, 2022 $ 34,754 (14,211,866) 88,472,935 293,140 39,931,031 114,519,994
Balance, shares at Dec. 31, 2022 34,754,265          
Stock-based compensation $ 69 2,168,673 2,168,742
Stock-based compensation expense, shares   68,750          
Repurchases of common stock (482,196) (482,196)
Other comprehensive income, net of tax 178,621 178,621
Net income (loss) (5,755,391) $ (5,755,391)
Common stock issued for option exercises, shares            
Balance at Mar. 31, 2023 $ 34,823 $ (14,694,062) $ 90,641,608 $ 471,761 $ 34,175,640 $ 110,629,770
Balance, shares at Mar. 31, 2023 34,823,015          
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Overview and Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Overview and Basis of Presentation

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR device and proprietary test cups (the “Co-Dx PCR Home™ platform”) that have been designed to bring affordable, reliable polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings. This platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. There is no guarantee the Co-Dx PCR Home platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform. 

 

Unaudited Consolidated Financial Statements

 

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed on March 16, 2023.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the condensed consolidated statements of operations and comprehensive income.

 

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

 

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2023, total accounts receivable was $5,686,589 with an allowance for uncollectable accounts of $2,984,393 resulting in a net amount of $2,702,196. At December 31, 2022, total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2023, the Company had $5,294,653 in inventory, comprised of $1,081,540 of finished goods, and $4,213,113 of raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Intangible Assets

 

Indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

 

Long-lived Assets

 

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 

Leases

 

The Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

 

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

 

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

Research and Development

 

Research and development costs are expensed when incurred. For the three months ended March 31, 2023, the Company expensed $5,014,060 of research and development costs, respectively. For the three months ended March 31, 2022, the Company expensed $3,771,327.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Comprehensive Income

 

Comprehensive income is comprised of unrealized gains and losses on marketable securities, net of income taxes.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2023. Two customers accounted for approximately 44% of total revenue for the three months ended March 31, 2023. Three customers together accounted for approximately 54% of total revenue for the three months ended March 31, 2022.

 

Four customers accounted for more than 10% of accounts receivable at March 31, 2023 and one customer accounted for more than 10% of accounts receivable at December 31, 2022. These customers together accounted for approximately 82% and 37% of accounts receivable at March 31, 2023 and December 31, 2022, respectively.

 

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, and Financial Instruments
 3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, and Financial Instruments

Note 3 - Cash, Cash Equivalents, and Financial Instruments

 

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 

   March 31, 2023 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $6,089,090   $        -   $-   $6,089,090   $6,089,090   $- 
Level 1:                              
Money market funds   270,290    -    -    270,290    270,290    - 
Subtotal   270,290    -    -    270,290    270,290    - 
Level 2:                              
U.S. treasury securities   68,294,247    -    626,288    68,920,535    -    68,920,535 
Subtotal   68,294,247    -    626,288    68,920,535    -    68,920,535 
Total  $74,653,627   $-   $626,288   $75,279,915   $6,359,380   $68,920,535 

 

   December 31, 2022 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $12,834,444   $       -   $-   $12,834,444   $12,834,444   $- 
Level 1:                              
Money market funds   146,359    -    -    146,359    146,359    - 
Subtotal   146,359    -    -    146,359    146,359    - 
Level 2:                              
U.S. treasury securities   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Subtotal   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Total  $80,873,628   $-   $389,241   $81,262,869   $22,973,803   $58,289,066 

 

Marketable investment securities held as of March 31, 2023 mature over the next 12 months.

 

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets, Net
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net

Note 4 – Intangible Assets, Net

 

Intangible assets, net consisted of the following:

 

   March 31, 2023
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (533,333)   560,667 
Total intangible assets     $27,195,000   $(533,333)  $26,661,667 

 

   December 31, 2022
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (426,667)   667,333 
Total intangible assets     $27,195,000   $(426,667)  $26,768,333 

 

(1) Based on weighted-average useful life established as of the acquisition date.

 

 

The expected future annual amortization expense of the Company’s intangible assets held as of March 31, 2023 is as follows:

 

Year Ending December 31,  Amortization Expense 
2023   258,003 
2024   302,664 
Total  $560,667 

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 5 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, by level within the fair value hierarchy:

 

                 
   March 31, 2023 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Cash equivalents  $-   $298,605   $-   $298,605 
Marketable securities (U.S. treasury bills and notes)   -    68,920,535    -    68,920,535 
Total assets measured at fair value  $-   $69,219,140   $-   $69,219,140 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $1,467,753   $1,467,753 
Contingent consideration - warrants   -    -    226,931    226,931 
Total liabilities measured at fair value  $-   $-   $1,694,684   $1,694,684 

 

                 
   December 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Cash equivalents  $-   $10,179,667   $-   $10,179,667 
Marketable securities (U.S. treasury bills and notes)   -    58,289,066    -    58,289,066 
Total assets measured at fair value  $-   $68,468,733   $-   $68,468,733 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $2,499,147   $2,499,147 
Contingent consideration - warrants   -    -    233,209    233,209 
Total liabilities measured at fair value  $-   $-   $2,732,356   $2,732,356 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of U.S. treasury bills and notes as of March 31, 2023 and December 31, 2022.

 

In connection with the acquisitions of IdMo and ACI on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2022  $2,732,356 
Change in fair value of contingent consideration issued for business acquisitions   (1,037,672)
Fair value as of March 31, 2023  $1,694,684 

 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   March 31, 2023   December 31, 2022 
Stock price  $1.48   $2.52 
Strike price  $9.13   $9.13 
Volatility   117.00%   75.00%
Risk-free rate   3.70%   4.10%
Expected term   3.8    4.0 

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue

Note 6 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Three Months Ended March 31, 
   2023   2022 
United States  $393,154   $14,218,398 
Rest of World   208,803    8,480,646 
Total  $601,957   $22,699,044 
Percentage of revenue by area:          
United States   65%   63%
Rest of World   35%   37%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 were as follows:

 

Balance as of December 31, 2022  $- 
Increase due to prepayments from customers   18,120 
Balance as of March 31, 2023  $18,120 

 

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share

Note 7 – Earnings Per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2023 and 2022, respectively:

 

   2023   2022 
   Three Months Ended March 31, 
   2023   2022 
Numerator        
Net income, as reported  $(5,755,391)  $11,714,595 
           
Denominator          
Weighted average shares, basic   29,483,540    33,935,570 
Dilutive effect of stock options, warrants and RSUs   -    775,906 
Shares used to compute diluted earnings per share   29,483,540    34,711,476 
           
Basic earnings per share  $(0.20)  $0.35 
Diluted earnings per share  $(0.20)  $0.34 

 

For the three months ended March 31, 2022, potentially dilutive securities of 1,271,304 were excluded from the calculation because their effect would have been anti-dilutive. The computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022, respectively, also excludes the approximately 1.4 million shares of common stock and approximately 465,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

 

As a result of incurring a net loss for the three months ended March 31, 2023, no potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of March 31, 2023, consisting of: (i) 2,732,517 restricted stock units and (ii) 120,445 options.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 8 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022, the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock. The number of awards available for issuance under the Incentive Plan was 5,518,290 at March 31, 2023.

 

Stock Options

 

The following table summarizes option activity during the three months ended March 31, 2023:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2022   1,040,572   $2.19   $1.37    5.88 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at March 31, 2023   1,040,572   $2.19   $1.37    5.64 
                     
Exercisable at March 31, 2023   1,040,572   $2.19   $1.37    5.64 

 

The aggregate intrinsic value of outstanding options at March 31, 2023 was approximately $0.3 million.

 

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. As of March 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2023:

 

  

Number of

RSUs

   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2022   2,426,725   $6.95 
Granted   692,500    2.82 
Vested   (68,750)   10.23 
Forfeited/Cancelled   -    - 
Unvested at March 31, 2023   3,050,475   $5.94 

 

As of March 31, 2023, there was approximately $14.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.1 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the three months ended March 31, 2023:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2022   485,000   $8.81   $2.43    4.0 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at March 31, 2023   485,000   $8.81   $1.09    3.8 

 

 

There were no warrants exercised during the three months ended March 31, 2023. The intrinsic value of warrants exercised during the three months ended March 31, 2022 was approximately $0.3 million. The aggregate intrinsic value of outstanding warrants at March 31, 2023 was approximately $0.1 million.

 

The total number of warrants exercisable at March 31, 2023 is 20,000. The ability to exercise the approximately 465,000 warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense as follows:

 

         
   Three Months Ended March 31, 
   2023   2022 

Cost of sales

  $

12,008

   $

12,327

 

Sales and marketing

   

529,117

    

388,017

 
General and administrative   

1,192,214

    

765,199

 
Research and development   

435,403

    

209,554

 
Total stock-based compensation expense  $2,168,742   $1,375,097 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 9 – Income Taxes

 

For the three months ended March 31, 2023, the Company recognized a benefit from income taxes of $2,259,811, representing an effective tax rate of 28.2%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2022, the Company recognized expense from income taxes of $1,386,087.

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10 – Commitments and Contingencies

 

Lease Obligations

 

The Company leases office space under a non-cancellable operating lease and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed. During the three months ended March 31, 2023, this lease was amended to extend the lease term. As a result of this amendment, the Company recognized an additional operating lease liability and corresponding operating right-of-use asset of $657,150.

 

For the three months ended March 31, 2023, components of lease expense are summarized as follows:

 

   Three Months Ended March 31, 2023 
Operating lease costs  $87,607 
Short-term lease costs   108,678 
Total lease costs  $196,285 

 

Short-term lease costs under month-to-month lease agreements are paid to related parties.

 

As of March 31, 2023, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2023  $245,226 
2024   353,919 
2025   368,291 
2026   61,680 
2027   - 
Thereafter   - 
Total lease payments   1,029,116 
Less: imputed interest   93,689 
Present value of operating lease liabilities   935,427 
Less: current portion   277,290 
Long-term portion  $658,137 

 

 

Other information related to operating leases was as follows:

 

  

Three Months Ended

March 31, 2023

 
Cash paid for operating leases included in operating cash flows  $188,835 
Remaining lease term of operating leases   3 years  
Discount rate of operating leases   6.7%

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two commercial litigation lawsuits in which plaintiffs are claiming they are owned certain remuneration based on alleged agreements with the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Share Repurchase Program
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Share Repurchase Program

Note 11 – Share Repurchase Program

 

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:

 

   Three Months Ended 
   March 31, 2023 
Balance, beginning of period   3,881,658 
Repurchases of common stock   309,012 
Balance, end of period   4,190,670 

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 12 – Subsequent Events

 

None.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Reclassifications

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 
Marketable Investment Securities

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the condensed consolidated statements of operations and comprehensive income.

 

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

 

 
Accounts Receivable

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2023, total accounts receivable was $5,686,589 with an allowance for uncollectable accounts of $2,984,393 resulting in a net amount of $2,702,196. At December 31, 2022, total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

 
Equity-Method Investments

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 
Inventory

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2023, the Company had $5,294,653 in inventory, comprised of $1,081,540 of finished goods, and $4,213,113 of raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 
Intangible Assets

Intangible Assets

 

Indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

 
Long-lived Assets

Long-lived Assets

 

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 
Business Combinations

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 
Leases

Leases

 

The Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

 

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

 

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

 
Revenue Recognition

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 
Deferred Revenue

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 
Research and Development

Research and Development

 

Research and development costs are expensed when incurred. For the three months ended March 31, 2023, the Company expensed $5,014,060 of research and development costs, respectively. For the three months ended March 31, 2022, the Company expensed $3,771,327.

 
Stock-based Compensation

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 
Net Income per Share

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 
Comprehensive Income

Comprehensive Income

 

Comprehensive income is comprised of unrealized gains and losses on marketable securities, net of income taxes.

 
Concentrations Risk and Significant Customers

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2023. Two customers accounted for approximately 44% of total revenue for the three months ended March 31, 2023. Three customers together accounted for approximately 54% of total revenue for the three months ended March 31, 2022.

 

Four customers accounted for more than 10% of accounts receivable at March 31, 2023 and one customer accounted for more than 10% of accounts receivable at December 31, 2022. These customers together accounted for approximately 82% and 37% of accounts receivable at March 31, 2023 and December 31, 2022, respectively.

 

 
Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, and Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of Cash,Cash Equivalents and Marketable Investment Securities

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 

   March 31, 2023 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $6,089,090   $        -   $-   $6,089,090   $6,089,090   $- 
Level 1:                              
Money market funds   270,290    -    -    270,290    270,290    - 
Subtotal   270,290    -    -    270,290    270,290    - 
Level 2:                              
U.S. treasury securities   68,294,247    -    626,288    68,920,535    -    68,920,535 
Subtotal   68,294,247    -    626,288    68,920,535    -    68,920,535 
Total  $74,653,627   $-   $626,288   $75,279,915   $6,359,380   $68,920,535 

 

   December 31, 2022 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $12,834,444   $       -   $-   $12,834,444   $12,834,444   $- 
Level 1:                              
Money market funds   146,359    -    -    146,359    146,359    - 
Subtotal   146,359    -    -    146,359    146,359    - 
Level 2:                              
U.S. treasury securities   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Subtotal   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Total  $80,873,628   $-   $389,241   $81,262,869   $22,973,803   $58,289,066 

 

Marketable investment securities held as of March 31, 2023 mature over the next 12 months.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets, Net (Tables)
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:

 

   March 31, 2023
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (533,333)   560,667 
Total intangible assets     $27,195,000   $(533,333)  $26,661,667 

 

   December 31, 2022
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (426,667)   667,333 
Total intangible assets     $27,195,000   $(426,667)  $26,768,333 

 

(1) Based on weighted-average useful life established as of the acquisition date.
Schedule of Future Amortization Expense

The expected future annual amortization expense of the Company’s intangible assets held as of March 31, 2023 is as follows:

 

Year Ending December 31,  Amortization Expense 
2023   258,003 
2024   302,664 
Total  $560,667 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Assets and Liabilities

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, by level within the fair value hierarchy:

 

                 
   March 31, 2023 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Cash equivalents  $-   $298,605   $-   $298,605 
Marketable securities (U.S. treasury bills and notes)   -    68,920,535    -    68,920,535 
Total assets measured at fair value  $-   $69,219,140   $-   $69,219,140 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $1,467,753   $1,467,753 
Contingent consideration - warrants   -    -    226,931    226,931 
Total liabilities measured at fair value  $-   $-   $1,694,684   $1,694,684 

 

                 
   December 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Cash equivalents  $-   $10,179,667   $-   $10,179,667 
Marketable securities (U.S. treasury bills and notes)   -    58,289,066    -    58,289,066 
Total assets measured at fair value  $-   $68,468,733   $-   $68,468,733 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $2,499,147   $2,499,147 
Contingent consideration - warrants   -    -    233,209    233,209 
Total liabilities measured at fair value  $-   $-   $2,732,356   $2,732,356 
Schedule of Changes in the Fair Value Measurement

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2022  $2,732,356 
Change in fair value of contingent consideration issued for business acquisitions   (1,037,672)
Fair value as of March 31, 2023  $1,694,684 
Schedule of Contingent Consideration Common Stock and Warrants

 

   March 31, 2023   December 31, 2022 
Stock price  $1.48   $2.52 
Strike price  $9.13   $9.13 
Volatility   117.00%   75.00%
Risk-free rate   3.70%   4.10%
Expected term   3.8    4.0 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Geographic Area

The following table sets forth revenue by geographic area:

 

   Three Months Ended March 31, 
   2023   2022 
United States  $393,154   $14,218,398 
Rest of World   208,803    8,480,646 
Total  $601,957   $22,699,044 
Percentage of revenue by area:          
United States   65%   63%
Rest of World   35%   37%
Schedule of Deferred Revenue

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 were as follows:

 

Balance as of December 31, 2022  $- 
Increase due to prepayments from customers   18,120 
Balance as of March 31, 2023  $18,120 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2023 and 2022, respectively:

 

   2023   2022 
   Three Months Ended March 31, 
   2023   2022 
Numerator        
Net income, as reported  $(5,755,391)  $11,714,595 
           
Denominator          
Weighted average shares, basic   29,483,540    33,935,570 
Dilutive effect of stock options, warrants and RSUs   -    775,906 
Shares used to compute diluted earnings per share   29,483,540    34,711,476 
           
Basic earnings per share  $(0.20)  $0.35 
Diluted earnings per share  $(0.20)  $0.34 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Option Activity

The following table summarizes option activity during the three months ended March 31, 2023:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2022   1,040,572   $2.19   $1.37    5.88 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at March 31, 2023   1,040,572   $2.19   $1.37    5.64 
                     
Exercisable at March 31, 2023   1,040,572   $2.19   $1.37    5.64 
Schedule of Outstanding Restricted Stock Units and Related Activity

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2023:

 

  

Number of

RSUs

   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2022   2,426,725   $6.95 
Granted   692,500    2.82 
Vested   (68,750)   10.23 
Forfeited/Cancelled   -    - 
Unvested at March 31, 2023   3,050,475   $5.94 
Schedule of Warrant Activity

The following table summarizes warrant activity during the three months ended March 31, 2023:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2022   485,000   $8.81   $2.43    4.0 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at March 31, 2023   485,000   $8.81   $1.09    3.8 
Schedule of Recognized Stock-based Compensation Expense

The Company recognized stock-based compensation expense as follows:

 

         
   Three Months Ended March 31, 
   2023   2022 

Cost of sales

  $

12,008

   $

12,327

 

Sales and marketing

   

529,117

    

388,017

 
General and administrative   

1,192,214

    

765,199

 
Research and development   

435,403

    

209,554

 
Total stock-based compensation expense  $2,168,742   $1,375,097 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Tables)
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Lease Expense

For the three months ended March 31, 2023, components of lease expense are summarized as follows:

 

   Three Months Ended March 31, 2023 
Operating lease costs  $87,607 
Short-term lease costs   108,678 
Total lease costs  $196,285 
Schedule of Maturities on Company Lease Liabilities

As of March 31, 2023, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2023  $245,226 
2024   353,919 
2025   368,291 
2026   61,680 
2027   - 
Thereafter   - 
Total lease payments   1,029,116 
Less: imputed interest   93,689 
Present value of operating lease liabilities   935,427 
Less: current portion   277,290 
Long-term portion  $658,137 
Schedule of Other Information Related to Operating Lease

Other information related to operating leases was as follows:

 

  

Three Months Ended

March 31, 2023

 
Cash paid for operating leases included in operating cash flows  $188,835 
Remaining lease term of operating leases   3 years  
Discount rate of operating leases   6.7%
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Share Repurchase Program (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of Treasury Stock

 

   Three Months Ended 
   March 31, 2023 
Balance, beginning of period   3,881,658 
Repurchases of common stock   309,012 
Balance, end of period   4,190,670 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Product Information [Line Items]      
Accounts receivable, before allowance for credit loss, current $ 5,686,589   $ 6,552,249
Uncollectable accounts 2,984,393   3,098,526
Accounts receivable, after allowance for credit loss, current 2,702,196   3,453,723
Inventory, net 5,294,653   5,310,473
Inventory, finished goods, gross 1,081,540   1,327,264
Inventory, raw materials, gross 4,213,113   $ 3,983,209
Research and development expense $ 5,014,060 $ 3,771,327  
Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]      
Product Information [Line Items]      
Concentration risk percentage 10.00%    
Two Customers Together [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]      
Product Information [Line Items]      
Concentration risk percentage 44.00%    
Three Customers Together [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]      
Product Information [Line Items]      
Concentration risk percentage 54.00%    
Four Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]      
Product Information [Line Items]      
Concentration risk percentage 10.00%    
One Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]      
Product Information [Line Items]      
Concentration risk percentage     10.00%
Customers Together [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]      
Product Information [Line Items]      
Concentration risk percentage 82.00%   37.00%
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Cash,Cash Equivalents and Marketable Investment Securities (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Line Items]    
Adjusted Cost $ 74,653,627 $ 80,873,628
Allowance for Credit Losses
Total Unrealized Gains / (Losses) 626,288 389,241
Fair Value 75,279,915 81,262,869
Cash and Cash Equivalents 6,359,380 22,973,803
Marketable Securities 68,920,535 58,289,066
Fair Value, Inputs, Level 1 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 270,290 146,359
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value 270,290 146,359
Cash and Cash Equivalents 270,290 146,359
Marketable Securities
Fair Value, Inputs, Level 2 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 68,294,247 67,892,825
Allowance for Credit Losses
Total Unrealized Gains / (Losses) 626,288 389,241
Fair Value 68,920,535 68,282,066
Cash and Cash Equivalents 9,993,000
Marketable Securities 68,920,535 58,289,066
Cash [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 6,089,090 12,834,444
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value 6,089,090 12,834,444
Cash and Cash Equivalents 6,089,090 12,834,444
Marketable Securities
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 270,290 146,359
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value 270,290 146,359
Cash and Cash Equivalents 270,290 146,359
Marketable Securities
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 68,294,247 67,892,825
Allowance for Credit Losses
Total Unrealized Gains / (Losses) 626,288 389,241
Fair Value 68,920,535 68,282,066
Cash and Cash Equivalents 9,993,000
Marketable Securities $ 68,920,535 $ 58,289,066
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Intangible Assets, Net (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 27,195,000 $ 27,195,000
Less accumulated amortization (533,333) (426,667)
Intangible assets, net $ 26,661,667 $ 26,768,333
In Process Research and Development [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful lives in years, term [1] Indefinite Indefinite
Intangible assets, gross $ 26,101,000 $ 26,101,000
Less accumulated amortization
Intangible assets, net 26,101,000 26,101,000
Noncompete Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 1,094,000 1,094,000
Less accumulated amortization (533,333) (426,667)
Intangible assets, net $ 560,667 $ 667,333
Estimated useful lives in years [1] 2 years 8 months 12 days 2 years 8 months 12 days
[1] Based on weighted-average useful life established as of the acquisition date.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Future Amortization Expense (Details)
Mar. 31, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2023 $ 258,003
2024 302,664
Total $ 560,667
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Fair Value Assets and Liabilities (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (U.S. treasury bills and notes) $ 68,920,535 $ 58,289,066
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (U.S. treasury bills and notes)
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (U.S. treasury bills and notes) 68,920,535 58,289,066
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 298,605 10,179,667
Marketable securities (U.S. treasury bills and notes) 68,920,535 58,289,066
Total assets measured at fair value 69,219,140 68,468,733
Contingent consideration - common stock 1,467,753 2,499,147
Contingent consideration - warrants 226,931 233,209
Total liabilities measured at fair value 1,694,684 2,732,356
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Marketable securities (U.S. treasury bills and notes)
Total assets measured at fair value
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 298,605 10,179,667
Marketable securities (U.S. treasury bills and notes) 68,920,535 58,289,066
Total assets measured at fair value 69,219,140 68,468,733
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Marketable securities (U.S. treasury bills and notes)
Total assets measured at fair value
Contingent consideration - common stock 1,467,753 2,499,147
Contingent consideration - warrants 226,931 233,209
Total liabilities measured at fair value $ 1,694,684 $ 2,732,356
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Changes in the Fair Value Measurement (Details)
 3 Months Ended
Mar. 31, 2023
USD ($)
Fair Value Disclosures [Abstract]  
Fair value as of December 31, 2022 $ 2,732,356
Change in fair value of contingent consideration issued for business acquisitions (1,037,672)
Fair value as of March 31, 2023 $ 1,694,684
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Contingent Consideration Common Stock and Warrants (Details)
Mar. 31, 2023
Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term 3 years 9 months 18 days 4 years
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 1.48 2.52
Measurement Input Strike Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 9.13 9.13
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 1.1700 0.7500
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 0.0370 0.0410
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Revenue by Geographic Area (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenue $ 601,957 $ 22,699,044
UNITED STATES    
Disaggregation of Revenue [Line Items]    
Revenue $ 393,154 $ 14,218,398
UNITED STATES | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 65.00% 63.00%
Rest of World [Member]    
Disaggregation of Revenue [Line Items]    
Revenue $ 208,803 $ 8,480,646
Rest of World [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 35.00% 37.00%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Deferred Revenue (Details)
 3 Months Ended
Mar. 31, 2023
USD ($)
Revenue from Contract with Customer [Abstract]  
Deferred revenue, beginning balance
Increase due to prepayments from customers 18,120
Deferred revenue, ending balance $ 18,120
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share [Abstract]    
Net income, as reported $ (5,755,391) $ 11,714,595
Weighted average shares, basic 29,483,540 33,935,570
Dilutive effect of stock options, warrants and RSUs 775,906
Shares used to compute diluted earnings per share 29,483,540 34,711,476
Basic earnings per share $ (0.20) $ 0.35
Diluted earnings per share $ (0.20) $ 0.34
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Details Narrative) - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 0 1,271,304
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 2,732,517  
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 120,445  
Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 1,400,000 1,400,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 465,000  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Option Activity (Details)
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Options Outstanding, Beginning | shares 1,040,572
Weighted Average Exercise Price Outstanding, Beginning $ 2.19
Weighted Average Fair Value Outstanding, Beginning $ 1.37
Weighted-average Remaining Contractual Life (years) Outstanding, Beginning 5 years 10 months 17 days
Number of Options Outstanding, Granted | shares
Weighted Average Exercise Price Granted
Weighted Average Fair Value Granted
Number of Options Outstanding, Expired | shares
Weighted Average Exercise Price Expired
Weighted Average Fair Value Expired
Number of Options Outstanding, Forfeited/Cancelled | shares
Weighted Average Exercise Price Forfeited/Cancelled
Weighted Average Fair Value Forfeited/Cancelled
Number of Options Outstanding, Exercised | shares
Weighted Average Exercise Price Exercised
Weighted Average Fair Value Exercised
Number of Options Outstanding, Ending | shares 1,040,572
Weighted Average Exercise Price Outstanding, Ending $ 2.19
Weighted Average Fair Value Outstanding, Ending $ 1.37
Weighted-average Remaining Contractual Life (years) Outstanding, Ending 5 years 7 months 20 days
Number of Options Exercisable Ending | shares 1,040,572
Weighted Average Exercise Price, Exercisable Ending $ 2.19
Weighted Average Fair Value, Exercisable Ending $ 1.37
Weighted-average Remaining Contractual Life (years), Exercisable Ending 5 years 7 months 20 days
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Outstanding Restricted Stock Units and Related Activity (Details) - Restricted Stock Units (RSUs) [Member]
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Restricted Stock Units, Outstanding Beginning | shares 2,426,725
Weighted Average Grant Date Fair Value, Outstanding Beginning | $ / shares $ 6.95
Number of Restricted Stock Units, Granted | shares 692,500
Weighted Average Grant Date Fair Value, Granted | $ / shares $ 2.82
Number of Restricted Stock Units, Vested | shares (68,750)
Weighted Average Grant Date Fair Value, Vested | $ / shares $ 10.23
Number of Restricted Stock Units, Forfeited/Cancelled | shares
Weighted Average Grant Date Fair Value, Forfeited/Cancelled | $ / shares
Number of Restricted Stock Units, Outstanding Ending | shares 3,050,475
Weighted Average Grant Date Fair Value, Outstanding Ending | $ / shares $ 5.94
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Warrant Activity (Details)
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Warrants Outstanding, Beginning | shares 485,000
Weighted Average Exercise Price, Beginning $ 8.81
Weighted Average fair value, Beginning $ 2.43
Weighted-average Remaining Contractual Life (Years) Outstanding 4 years
Number of Warrants Outstanding, Granted | shares
Weighted Average Exercise Price, Granted
Weighted Average Fair Value, Granted
Number of Warrants Outstanding, Expired | shares
Weighted Average Exercise Price, Expired
Weighted Average Fair Value, Expired
Number of Warrants Outstanding, Forfeited/Cancelled | shares
Weighted Average Exercise Price, Forfeited/Cancelled
Weighted Average Fair Value, Forfeited/Cancelled
Number of Warrants Outstanding, Exercised | shares
Weighted Average Exercise Price, Exercised
Weighted Average Fair Value, Exercised
Number of Warrants Outstanding, Ending | shares 485,000
Weighted Average Exercise Price, Ending $ 8.81
Weighted Average Fair Value, Ending $ 1.09
Weighted-average Remaining Contractual Life (Years) Outstanding 3 years 9 months 18 days
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Recognized Stock-based Compensation Expense (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense $ 2,168,742 $ 1,375,097
Cost Of Sale [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense 12,008 12,327
Sales And Marketing [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense 529,117 388,017
General And Administrative [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense 1,192,214 765,199
Research And Development [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total stock-based compensation expense $ 435,403 $ 209,554
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Details Narrative) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Aug. 31, 2022
Warrant [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Aggregate intrinsic value of options outstanding $ 0.1  
Intrinsic value of warrants exercised $ 0.3  
Warrants exercisable 20,000  
Warrants to purchase a common stock 465,000  
Stock Options [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Aggregate intrinsic value of options outstanding $ 0.3  
Restricted Stock Units (RSUs) [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Unrecognized stock-based compensation $ 14.5  
Unrecognized stock-based compensation recognition period 2 years 1 month 6 days  
2015 Long Term Incentive Plan [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of common shares availalble for issuance 5,518,290 12,000,000
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) $ 2,259,811 $ (1,386,087)
Effective income tax rate reconciliation, percent 28.20%  
Effective income tax rate reconciliation, percent 21.00%  
Income tax expense (benefit) $ (2,259,811) $ 1,386,087
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Lease Expense (Details)
 3 Months Ended
Mar. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Operating lease costs $ 87,607
Short-term lease costs 108,678
Total lease costs $ 196,285
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Maturities on Company Lease Liabilities (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
2023 $ 245,226  
2024 353,919  
2025 368,291  
2026 61,680  
2027  
Thereafter  
Total lease payments 1,029,116  
Less: imputed interest 93,689  
Present value of operating lease liabilities 935,427  
Less: current portion 277,290 $ 297,209
Long-term portion $ 658,137 $ 50,708
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Other Information Related to Operating Lease (Details)
 3 Months Ended
Mar. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Cash paid for operating leases included in operating cash flows $ 188,835
Remaining lease term of operating leases 3 years
Discount rate of operating leases 6.70%
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details Narrative) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Operating lease right-of-use asset $ 952,176 $ 372,115
Operating lease liabilities 935,427  
Lease Amendment [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Operating lease right-of-use asset 657,150  
Operating lease liabilities $ 657,150  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Treasury Stock (Details)
 3 Months Ended
Mar. 31, 2023
shares
Equity [Abstract]  
Treasury stock, Beginning Balance 3,881,658
Repurchases of common stock 309,012
Treasury stock, Ending Balance 4,190,670
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Share Repurchase Program (Details Narrative)
$ in Millions
Mar. 31, 2022
USD ($)
Equity [Abstract]  
Stock repurchase program authorized amount $ 30.0
XML 61 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001692415 2023-01-01 2023-03-31 0001692415 2023-05-10 0001692415 2023-03-31 0001692415 2022-12-31 0001692415 2022-01-01 2022-03-31 0001692415 2021-12-31 0001692415 2022-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001692415 us-gaap:CommonStockMember 2022-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001692415 us-gaap:RetainedEarningsMember 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001692415 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001692415 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001692415 us-gaap:CommonStockMember 2023-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001692415 us-gaap:RetainedEarningsMember 2023-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001692415 us-gaap:CommonStockMember 2022-03-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001692415 us-gaap:RetainedEarningsMember 2022-03-31 0001692415 CODX:CustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:ThreeCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:FourCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:OneCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:CustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:CustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 us-gaap:CashMember 2023-03-31 0001692415 us-gaap:CashMember 2023-01-01 2023-03-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-03-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-03-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0001692415 us-gaap:CashMember 2022-12-31 0001692415 us-gaap:CashMember 2022-01-01 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 2022-01-01 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-03-31 0001692415 us-gaap:NoncompeteAgreementsMember 2023-03-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2023-03-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2023-03-31 0001692415 CODX:MeasurementInputStrikePriceMember 2022-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001692415 country:US 2023-01-01 2023-03-31 0001692415 country:US 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember 2023-01-01 2023-03-31 0001692415 CODX:RestOfWorldMember 2022-01-01 2022-03-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001692415 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001692415 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2022-08-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2023-03-31 0001692415 CODX:StockOptionsMember 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001692415 us-gaap:WarrantMember 2023-03-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001692415 CODX:CostOfSaleMember 2023-01-01 2023-03-31 0001692415 CODX:CostOfSaleMember 2022-01-01 2022-03-31 0001692415 CODX:SalesAndMarketingMember 2023-01-01 2023-03-31 0001692415 CODX:SalesAndMarketingMember 2022-01-01 2022-03-31 0001692415 CODX:GeneralAndAdministrativeMember 2023-01-01 2023-03-31 0001692415 CODX:GeneralAndAdministrativeMember 2022-01-01 2022-03-31 0001692415 CODX:ResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001692415 CODX:ResearchAndDevelopmentMember 2022-01-01 2022-03-31 0001692415 CODX:LeaseAmendmentMember 2023-03-31 iso4217:USD shares iso4217:USD shares pure utr:acre 0001692415 false Q1 --12-31 10-Q true 2023-03-31 2023 false 001-38148 CO-DIAGNOSTICS, INC. UT 46-2609396 2401 S. Foothill Drive Suite D Salt Lake City UT 84109 (801) 438-1036 Common Stock CODX NASDAQ Yes Yes Non-accelerated Filer true false false 30263536 6359380 22973803 68920535 58289066 2702196 3453723 5294653 5310473 1695480 1870419 913175 761187 37500 75000 85922919 92733671 2510083 2539483 952176 372115 26661667 26768333 950001 672679 116996846 123086281 829819 952296 1492611 934447 277290 297209 992229 1689471 18120 3610069 3873423 1193080 1181284 203335 2417987 658137 50708 702455 1042885 2757007 4692864 6367076 8566287 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 34823015 30632345 34754265 30872607 34823 34754 4190670 3881658 14694062 14211866 90641608 88472935 471761 293140 34175640 39931031 110629770 114519994 116996846 123086281 601957 22699044 502241 3281951 99716 19417093 1706331 2652148 3013965 2922195 5014060 3771327 316010 247264 10050366 9592934 -9950650 9824159 202372 11393 418082 -93421 1037672 3379890 277322 -21339 1935448 3276523 -8015202 13100682 -2259811 1386087 -5755391 11714595 178621 178621 -5576770 11714595 -0.20 0.35 -0.20 0.34 29483540 33935570 29483540 34711476 -5755391 11714595 316010 247264 2168742 1375097 1037672 3379890 7449 8762 277322 -21339 -93421 -2214652 -1359716 -114133 47862 -865660 871083 -60451 -1042932 -15821 3088944 18120 -150000 11796 2745803 435686 -641604 -5499435 7805838 179944 396600 30539621 1255266 40992469 -10632792 858666 150001 482196 -482196 150001 -16614423 8814505 22973803 88607234 6359380 97421739 29500 192056 657150 681327 34754265 34754 -14211866 88472935 293140 39931031 114519994 68750 69 2168673 2168742 482196 482196 178621 178621 -5755391 -5755391 34823015 34823 -14694062 90641608 471761 34175640 110629770 33819862 33820 80271999 54169279 134475100 33819862 33820 80271999 54169279 134475100 45456 45 49956 50001 50000 50 99950 100000 68750 69 1375028 1375097 11714595 11714595 11714595 11714595 33984068 33984 81796933 65883874 147714793 33984068 33984 81796933 65883874 147714793 <p id="xdx_80F_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvqqRMBTtCqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_82B_z2ZRcyO4Z5I8">Overview and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR device and proprietary test cups (the “Co-Dx PCR Home™ platform”) that have been designed to bring affordable, reliable polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings. This platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. There is no guarantee the Co-Dx PCR Home platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed on March 16, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_z4L6sUM9g1Jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_827_znTlVSscaZW">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ReclassificationsPolicytextBlock_z4BScy795Ca1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z7gninwvaFXc">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zc4ej06iMkq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z1SUvpY7EfP9">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2023 and December 31, 2022. <span style="background-color: white">The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--MarketableSecuritiesPolicy_zkuuStWVF7gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zhkUbtQPSgF5">Marketable Investment Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the condensed consolidated statements of operations and comprehensive income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zp5W93qkuOI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuKUul1Lp9ph">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2023, total accounts receivable was $<span id="xdx_908_eus-gaap--AccountsReceivableGrossCurrent_iI_c20230331_zpIYe5AVoI1g" title="Accounts receivable">5,686,589</span> with an allowance for uncollectable accounts of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20230331_zkkYnmDrWQ44" title="Doubtful accounts">2,984,393</span> resulting in a net amount of $<span id="xdx_90C_eus-gaap--AccountsReceivableNetCurrent_iI_c20230331_zQvvfSE95EHa" title="Accounts receivable, net">2,702,196</span>. At December 31, 2022, total accounts receivable was $<span id="xdx_903_eus-gaap--AccountsReceivableGrossCurrent_iI_c20221231_z1Vl3pbs1cvk" title="Accounts receivable, before allowance for credit loss, current">6,552,249</span> with an allowance for uncollectable accounts of $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zNdn3fKZnEEh" title="Uncollectable accounts">3,098,526</span> resulting in a net amount of $<span id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231_zg9VcbO4L1h5" title="Accounts receivable, after allowance for credit loss, current">3,453,723</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EquityMethodInvestmentsPolicy_zhAOlzbvyVuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zZ8ZsI9qu3U3">Equity-Method Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zqTBL83pJYR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zv5loJO028Ff">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2023, the Company had $<span id="xdx_906_eus-gaap--InventoryNet_iI_c20230331_zGVa5VJRQPx1" title="Inventory">5,294,653</span> in inventory, comprised of $<span id="xdx_902_eus-gaap--InventoryFinishedGoods_iI_c20230331_zfKet8BUUnpl" title="Inventory finished goods">1,081,540</span> of finished goods, and $<span id="xdx_901_eus-gaap--InventoryRawMaterials_iI_c20230331_zVsxW3fwXpPg" title="Inventory raw materials">4,213,113</span> of raw materials. At December 31, 2022, the Company had $<span id="xdx_902_eus-gaap--InventoryNet_iI_c20221231_zJcjM0nzoXFk" title="Inventory, net">5,310,473</span> in inventory, of which $<span id="xdx_90E_eus-gaap--InventoryFinishedGoods_iI_c20221231_z0pSl5qh3HHg" title="Inventory, finished goods, gross">1,327,264</span> was finished goods and $<span id="xdx_908_eus-gaap--InventoryRawMaterials_iI_c20221231_zqC2VKvIdQUg" title="Inventory, raw materials, gross">3,983,209</span> was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zKY4rrIbXtXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zTdQam6sKLY5">Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zvXK06c0aJNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zkWhIWGsi6sl">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets, including property and equipment, finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zALde5uTK2t6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zaCRyRSp1Ut4">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z0ZWkb4lJJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zhjgaUbkkv4j">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zbviftxrHuZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z1C8xHy47U89">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_znD3YBtsXhyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zLYhTvvIWnNh">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMgWgMTkrG53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zNZBtv4ZQLlc">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. For the three months ended March 31, 2023, the Company expensed $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zoouivUqAya6" title="Research and development">5,014,060</span> of research and development costs, respectively. For the three months ended March 31, 2022, the Company expensed $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zXrKVhnY7j2a" title="Research and development expense">3,771,327</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zyLOYi0nqL6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zyU0FlqXCyx2">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. <span style="background-color: white">When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zH7HloPadcYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zndNfGV7id14">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1jYOCZO7Eei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zH8xWGf3exb8">Net Income per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zKxPqaJPWS3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zWycgvlluQPh">Comprehensive Income</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive income is comprised of unrealized gains and losses on marketable securities, net of income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zsNYxFdNcang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zAOEOWtecQ92">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zIDMVko5Hapd" title="Concentration risk percentage">10</span>% or more of the total revenue for the three months ended March 31, 2023. Two customers accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBRloBfKtQQ5">44</span>% of total revenue for the three months ended March 31, 2023. Three customers together accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4fzWG5l95S6" title="Concentration risk percentage">54</span>% of total revenue for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four customers accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zXL2FWRnQGxd" title="Concentration risk percentage">10</span>% of accounts receivable at March 31, 2023 and one customer accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zGUC5Yg15FA4" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2022. These customers together accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z9yjGoW3IXN4" title="Concentration risk percentage">82</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zYYM0m7qT6Dj" title="Concentration risk percentage">37</span>% of accounts receivable at March 31, 2023 and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfrZJol7Z4c8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z3MCRdqVnyZb">Recently Issued Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p id="xdx_855_z10mT2qLJl47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_844_ecustom--ReclassificationsPolicytextBlock_z4BScy795Ca1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z7gninwvaFXc">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zc4ej06iMkq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z1SUvpY7EfP9">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2023 and December 31, 2022. <span style="background-color: white">The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--MarketableSecuritiesPolicy_zkuuStWVF7gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zhkUbtQPSgF5">Marketable Investment Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the condensed consolidated statements of operations and comprehensive income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zp5W93qkuOI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuKUul1Lp9ph">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2023, total accounts receivable was $<span id="xdx_908_eus-gaap--AccountsReceivableGrossCurrent_iI_c20230331_zpIYe5AVoI1g" title="Accounts receivable">5,686,589</span> with an allowance for uncollectable accounts of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20230331_zkkYnmDrWQ44" title="Doubtful accounts">2,984,393</span> resulting in a net amount of $<span id="xdx_90C_eus-gaap--AccountsReceivableNetCurrent_iI_c20230331_zQvvfSE95EHa" title="Accounts receivable, net">2,702,196</span>. At December 31, 2022, total accounts receivable was $<span id="xdx_903_eus-gaap--AccountsReceivableGrossCurrent_iI_c20221231_z1Vl3pbs1cvk" title="Accounts receivable, before allowance for credit loss, current">6,552,249</span> with an allowance for uncollectable accounts of $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zNdn3fKZnEEh" title="Uncollectable accounts">3,098,526</span> resulting in a net amount of $<span id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231_zg9VcbO4L1h5" title="Accounts receivable, after allowance for credit loss, current">3,453,723</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5686589 2984393 2702196 6552249 3098526 3453723 <p id="xdx_848_eus-gaap--EquityMethodInvestmentsPolicy_zhAOlzbvyVuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zZ8ZsI9qu3U3">Equity-Method Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zqTBL83pJYR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zv5loJO028Ff">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2023, the Company had $<span id="xdx_906_eus-gaap--InventoryNet_iI_c20230331_zGVa5VJRQPx1" title="Inventory">5,294,653</span> in inventory, comprised of $<span id="xdx_902_eus-gaap--InventoryFinishedGoods_iI_c20230331_zfKet8BUUnpl" title="Inventory finished goods">1,081,540</span> of finished goods, and $<span id="xdx_901_eus-gaap--InventoryRawMaterials_iI_c20230331_zVsxW3fwXpPg" title="Inventory raw materials">4,213,113</span> of raw materials. At December 31, 2022, the Company had $<span id="xdx_902_eus-gaap--InventoryNet_iI_c20221231_zJcjM0nzoXFk" title="Inventory, net">5,310,473</span> in inventory, of which $<span id="xdx_90E_eus-gaap--InventoryFinishedGoods_iI_c20221231_z0pSl5qh3HHg" title="Inventory, finished goods, gross">1,327,264</span> was finished goods and $<span id="xdx_908_eus-gaap--InventoryRawMaterials_iI_c20221231_zqC2VKvIdQUg" title="Inventory, raw materials, gross">3,983,209</span> was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5294653 1081540 4213113 5310473 1327264 3983209 <p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zKY4rrIbXtXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zTdQam6sKLY5">Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zvXK06c0aJNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zkWhIWGsi6sl">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets, including property and equipment, finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zALde5uTK2t6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zaCRyRSp1Ut4">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z0ZWkb4lJJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zhjgaUbkkv4j">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zbviftxrHuZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z1C8xHy47U89">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_znD3YBtsXhyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zLYhTvvIWnNh">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMgWgMTkrG53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zNZBtv4ZQLlc">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. For the three months ended March 31, 2023, the Company expensed $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zoouivUqAya6" title="Research and development">5,014,060</span> of research and development costs, respectively. For the three months ended March 31, 2022, the Company expensed $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zXrKVhnY7j2a" title="Research and development expense">3,771,327</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5014060 3771327 <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zyLOYi0nqL6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zyU0FlqXCyx2">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. <span style="background-color: white">When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zH7HloPadcYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zndNfGV7id14">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1jYOCZO7Eei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zH8xWGf3exb8">Net Income per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zKxPqaJPWS3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zWycgvlluQPh">Comprehensive Income</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive income is comprised of unrealized gains and losses on marketable securities, net of income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zsNYxFdNcang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zAOEOWtecQ92">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zIDMVko5Hapd" title="Concentration risk percentage">10</span>% or more of the total revenue for the three months ended March 31, 2023. Two customers accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBRloBfKtQQ5">44</span>% of total revenue for the three months ended March 31, 2023. Three customers together accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4fzWG5l95S6" title="Concentration risk percentage">54</span>% of total revenue for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four customers accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zXL2FWRnQGxd" title="Concentration risk percentage">10</span>% of accounts receivable at March 31, 2023 and one customer accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zGUC5Yg15FA4" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2022. These customers together accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z9yjGoW3IXN4" title="Concentration risk percentage">82</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zYYM0m7qT6Dj" title="Concentration risk percentage">37</span>% of accounts receivable at March 31, 2023 and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.44 0.54 0.10 0.10 0.82 0.37 <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfrZJol7Z4c8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z3MCRdqVnyZb">Recently Issued Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p id="xdx_807_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_zu6zBWzJ7Ajg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 - <span id="xdx_820_zsJvgQI3EMr7">Cash, Cash Equivalents, and Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zjqdBmgon4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zMqDV3vNuz92" style="display: none">Schedule of Cash,Cash Equivalents and Marketable Investment Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allowance for Credit Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Unrealized Gains / (Losses)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cash and Cash Equivalents</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zIUqevCLhvBj" style="width: 6%; text-align: right" title="Adjusted Cost">6,089,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zEaU8AuSS7f9" style="width: 6%; text-align: right" title="Allowance for Credit Losses">        <span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z5lHsoi5WIij" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zk2NfwrEYksk" style="width: 6%; text-align: right" title="Fair Value">6,089,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zwNHEj8porfg" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">6,089,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zZh49ZU8AKp9" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAULU2mNXTO7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">270,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5vnbZnczJG5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8BgbHZTibYj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0652">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3iZuPgLPQzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">270,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3xROgN0fu94" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">270,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZJ6SSVFoagb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwllRFXr0M3l" style="text-align: right" title="Adjusted Cost">270,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zMIYiF5MLuQi" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOXiIgPN8QE" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZNlAdPhGipg" style="text-align: right" title="Fair Value">270,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgwagtD4tQPh" style="text-align: right" title="Cash and Cash Equivalents">270,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zE9quPRf895b" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziajsfv2IJA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">68,294,247</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEZxxug1oq8e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6SjYgw6Dmg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">626,288</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziW8apAEUcxi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zoHfeYilSdGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zlp38bdaooeb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziZkOkMh6JQc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">68,294,247</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxtSLckqIYDk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z27r9tJpd8Bi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">626,288</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEInuXNL6dKb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPoNZkdkhaFa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zvreliOprP98" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331_zitPlSHwolPa" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">74,653,627</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331_zEpZmBcSmICj" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331_zLfdQ12ys3r6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">626,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--TradingSecurities_iI_c20230331_zZWcdqVP6Cbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">75,279,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_z9jyfP4QN8N9" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">6,359,380</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_c20230331_zG7lqoG2Wavk" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">68,920,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allowance for Credit Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Unrealized Gains / (Losses)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cash and Cash Equivalents</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zaZSV5SYLlvl" style="width: 6%; text-align: right" title="Adjusted Cost">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zdax4rPgMOB6" style="width: 6%; text-align: right" title="Allowance for Credit Losses">       <span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zpjc54kzBIu9" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zSIM9WBji0hb" style="width: 6%; text-align: right" title="Fair Value">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zRQvHkL3j0od" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zuNQvonZMmW1" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD0xmcHAPJeg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaaCPcFAHLc2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4ZoPdFlMNGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXZrv5fVVPpl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVLGiMMOXKRd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpFGE4p57jN2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zL605qD1Wc08" style="text-align: right" title="Adjusted Cost">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zl7wUxqAHAx6" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFO6Mfo9h54l" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4SbBlb0TDuh" style="text-align: right" title="Fair Value">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z0swdsi1f3Ob" style="text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwJB71hdwX2f" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTX6WutbWmj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWDcCjPnlRW9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zhWsCXMgQDac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNKBEjUn1dFa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkA6gbWdm3b6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHwrtua6bjtb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaIwZUpn6aW9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zglr0nPN8d27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zB6OcDXrLPfe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLcYWAzdxoIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJ4HrcQsA2Ok" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zlXbmJxbCJ6b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231_zH1x5FSkVStj" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">80,873,628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231_z2y65VmGndr6" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_zxSIFFksdaL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--TradingSecurities_iI_c20221231_zewD8xwBb4j6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">81,262,869</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_z1yM4muI9V99" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">22,973,803</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20221231_zLyUojfkQCjd" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Marketable investment securities held as of March 31, 2023 mature over the next 12 months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_8AF_zfCCWqERUi7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zjqdBmgon4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zMqDV3vNuz92" style="display: none">Schedule of Cash,Cash Equivalents and Marketable Investment Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allowance for Credit Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Unrealized Gains / (Losses)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cash and Cash Equivalents</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zIUqevCLhvBj" style="width: 6%; text-align: right" title="Adjusted Cost">6,089,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zEaU8AuSS7f9" style="width: 6%; text-align: right" title="Allowance for Credit Losses">        <span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z5lHsoi5WIij" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zk2NfwrEYksk" style="width: 6%; text-align: right" title="Fair Value">6,089,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zwNHEj8porfg" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">6,089,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zZh49ZU8AKp9" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAULU2mNXTO7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">270,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5vnbZnczJG5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8BgbHZTibYj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0652">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3iZuPgLPQzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">270,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3xROgN0fu94" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">270,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZJ6SSVFoagb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwllRFXr0M3l" style="text-align: right" title="Adjusted Cost">270,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zMIYiF5MLuQi" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOXiIgPN8QE" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZNlAdPhGipg" style="text-align: right" title="Fair Value">270,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgwagtD4tQPh" style="text-align: right" title="Cash and Cash Equivalents">270,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zE9quPRf895b" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziajsfv2IJA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">68,294,247</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEZxxug1oq8e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6SjYgw6Dmg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">626,288</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziW8apAEUcxi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zoHfeYilSdGg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zlp38bdaooeb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziZkOkMh6JQc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">68,294,247</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxtSLckqIYDk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z27r9tJpd8Bi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">626,288</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TradingSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEInuXNL6dKb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPoNZkdkhaFa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zvreliOprP98" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20230331_zitPlSHwolPa" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">74,653,627</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20230331_zEpZmBcSmICj" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20230331_zLfdQ12ys3r6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">626,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--TradingSecurities_iI_c20230331_zZWcdqVP6Cbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">75,279,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_z9jyfP4QN8N9" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">6,359,380</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_c20230331_zG7lqoG2Wavk" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">68,920,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allowance for Credit Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Unrealized Gains / (Losses)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cash and Cash Equivalents</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zaZSV5SYLlvl" style="width: 6%; text-align: right" title="Adjusted Cost">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zdax4rPgMOB6" style="width: 6%; text-align: right" title="Allowance for Credit Losses">       <span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zpjc54kzBIu9" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zSIM9WBji0hb" style="width: 6%; text-align: right" title="Fair Value">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zRQvHkL3j0od" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zuNQvonZMmW1" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD0xmcHAPJeg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaaCPcFAHLc2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4ZoPdFlMNGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXZrv5fVVPpl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVLGiMMOXKRd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpFGE4p57jN2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zL605qD1Wc08" style="text-align: right" title="Adjusted Cost">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zl7wUxqAHAx6" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFO6Mfo9h54l" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4SbBlb0TDuh" style="text-align: right" title="Fair Value">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z0swdsi1f3Ob" style="text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwJB71hdwX2f" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTX6WutbWmj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWDcCjPnlRW9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zhWsCXMgQDac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNKBEjUn1dFa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkA6gbWdm3b6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHwrtua6bjtb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaIwZUpn6aW9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zglr0nPN8d27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zB6OcDXrLPfe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLcYWAzdxoIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJ4HrcQsA2Ok" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zlXbmJxbCJ6b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231_zH1x5FSkVStj" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">80,873,628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231_z2y65VmGndr6" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_zxSIFFksdaL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--TradingSecurities_iI_c20221231_zewD8xwBb4j6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">81,262,869</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_z1yM4muI9V99" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">22,973,803</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20221231_zLyUojfkQCjd" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Marketable investment securities held as of March 31, 2023 mature over the next 12 months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 6089090 6089090 6089090 270290 270290 270290 270290 270290 270290 68294247 626288 68920535 68920535 68294247 626288 68920535 68920535 74653627 626288 75279915 6359380 68920535 12834444 12834444 12834444 146359 146359 146359 146359 146359 146359 67892825 389241 68282066 9993000 58289066 67892825 389241 68282066 9993000 58289066 80873628 389241 81262869 22973803 58289066 <p id="xdx_801_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zKLohl1G1HH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_825_z7tXUfBpHla8">Intangible Assets, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_znedvw5dNm48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zY0oKuFovpH" style="display: none">Schedule of Intangible Assets, Net</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful Life <span id="xdx_F5E_ztRp7BDQZMo9">(1)</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center"><span id="xdx_90B_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20230101__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zJQGyQSxduI4" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zS1gaHwB1Xj5" style="width: 18%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLeOiGVyVjga" style="width: 16%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zNesVWVhEZkk" style="width: 16%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition agreements</td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zYwunBJM0Bo8" title="Estimated useful lives in years">2.7</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zhS2VOE7aHG3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zHB5MWjd6Ko5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(533,333</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zf0RbxqcMtR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">560,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total intangible assets</td><td> </td> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331_zi4bqNZAK91d" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331_zSK9Qc8HZof2" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(533,333</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20230331_z9swoh1oNa7a" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,661,667</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful Life <span id="xdx_F5F_z820xziHuzhf">(1)</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center"><span id="xdx_90A_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zJKaOt2oU0f9" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zAjWGVL9bpok" style="width: 18%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zUCCOPMy4wqh" style="width: 16%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zmbHHVa6drjb" style="width: 16%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zTPGz68cUEU3" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zEgaE4EdOJSj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zlSU5edGCrze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zBLJTDZb7RFf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">667,333</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231_zcBrzHsxyja3" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231_zW1l7eB5fJTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231_zTzH0zgSuP8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,768,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span id="xdx_F03_z3iqDhs7gGyi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zEsFnDvvXwfh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on weighted-average useful life established as of the acquisition date.</span></td></tr> </table> <p id="xdx_8A7_zB55HLBCH8wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPy70orL6Vfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected future annual amortization expense of the Company’s intangible assets held as of March 31, 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zjLn6EMCr7Sl" style="display: none">Schedule of Future Amortization Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230331_zlEfXITA6TGa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzZiM_z9G8tsKH5FU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">258,003</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzZiM_zV6p2fkRBiT2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,664</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzZiM_zTpRvAajYmt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">560,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zURsaHHo4NDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_znedvw5dNm48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zY0oKuFovpH" style="display: none">Schedule of Intangible Assets, Net</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful Life <span id="xdx_F5E_ztRp7BDQZMo9">(1)</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center"><span id="xdx_90B_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20230101__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zJQGyQSxduI4" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zS1gaHwB1Xj5" style="width: 18%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLeOiGVyVjga" style="width: 16%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zNesVWVhEZkk" style="width: 16%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition agreements</td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zYwunBJM0Bo8" title="Estimated useful lives in years">2.7</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zhS2VOE7aHG3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zHB5MWjd6Ko5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(533,333</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zf0RbxqcMtR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">560,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total intangible assets</td><td> </td> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331_zi4bqNZAK91d" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331_zSK9Qc8HZof2" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(533,333</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20230331_z9swoh1oNa7a" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,661,667</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful Life <span id="xdx_F5F_z820xziHuzhf">(1)</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center"><span id="xdx_90A_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zJKaOt2oU0f9" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zAjWGVL9bpok" style="width: 18%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zUCCOPMy4wqh" style="width: 16%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zmbHHVa6drjb" style="width: 16%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zTPGz68cUEU3" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zEgaE4EdOJSj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zlSU5edGCrze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zBLJTDZb7RFf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">667,333</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231_zcBrzHsxyja3" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231_zW1l7eB5fJTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231_zTzH0zgSuP8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,768,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span id="xdx_F03_z3iqDhs7gGyi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zEsFnDvvXwfh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on weighted-average useful life established as of the acquisition date.</span></td></tr> </table> Indefinite 26101000 26101000 P2Y8M12D 1094000 -533333 560667 27195000 -533333 26661667 Indefinite 26101000 26101000 P2Y8M12D 1094000 -426667 667333 27195000 -426667 26768333 <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPy70orL6Vfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected future annual amortization expense of the Company’s intangible assets held as of March 31, 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zjLn6EMCr7Sl" style="display: none">Schedule of Future Amortization Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230331_zlEfXITA6TGa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzZiM_z9G8tsKH5FU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">258,003</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzZiM_zV6p2fkRBiT2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,664</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzZiM_zTpRvAajYmt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">560,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 258003 302664 560667 <p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zsLIheXwc0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_82B_zQ5NbfiCSaB1">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following three levels of inputs are used to measure the fair value of financial assets and liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zVBcH1byNO14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zwL5YGWPCyr5" style="display: none">Schedule of Fair Value Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXNPRNbV6S1e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7PtBl1Ue7Y4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztI7upHCJjrf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zU1h2Bcn4o5d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_zBzrwPS2uOs3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">298,605</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">298,605</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zdQXO4JImMKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zT4nz2dDrrl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,219,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,219,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zOrhDnJnIpY5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zS3xdYqNCWre" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">226,931</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">226,931</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zzBS52eW7332" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,694,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,694,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjj12dKP9sh9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpCRvgjRYLSh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zxMQC9c7dI61" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoj6RBPFLoUg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_zP7boueYFjq5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,179,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,179,667</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zXgBdXrgWH8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zisMqB94HX13" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,468,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,468,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_ztVj3P0n65pc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zsV0eKqopfK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zlFB9rLy3qp8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_ze2lsasLUHH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are measured at fair value on a recurring basis consist of U.S. treasury bills and notes as of March 31, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisitions of IdMo and ACI on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z1i6M0IOOQb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zNYAyn9ogZLj" style="display: none">Schedule of Changes in the Fair Value Measurement</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20230101__20230331_zPNGGXqbtWqa" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_pp0p0_z70cJWxROCyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,732,356</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_zkQuanjP6Azf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of contingent consideration issued for business acquisitions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,037,672</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_z2bsUt4Xtv09" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,694,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zCrToWAEoHuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:</span></p> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zzUN5jVpCpvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_z1bZKgSl0Dn" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zubiLC3gu1u7" style="width: 16%; text-align: right" title="Warrants measurement input">1.48</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zRGKyOegupSd" style="width: 16%; text-align: right" title="Warrants measurement input">2.52</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zVGmKsh9azW3" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zTsEq164e228" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHbJBjmr96If" title="Warrants measurement input">117.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zdyWNcht0oB8" title="Warrants measurement input">75.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zyz3v8lcghe8" title="Warrants measurement input">3.70</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zex4SwxUYfe5" title="Warrants measurement input">4.10</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230331_zC1tqhnOJPpk" title="Expected term">3.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_z5e46RI7VRm9" title="Expected term">4.0</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_z6gIHXdZn9Ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Other Financial Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zVBcH1byNO14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zwL5YGWPCyr5" style="display: none">Schedule of Fair Value Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXNPRNbV6S1e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7PtBl1Ue7Y4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztI7upHCJjrf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zU1h2Bcn4o5d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_zBzrwPS2uOs3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">298,605</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">298,605</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zdQXO4JImMKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,920,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zT4nz2dDrrl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,219,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,219,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zOrhDnJnIpY5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zS3xdYqNCWre" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">226,931</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">226,931</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zzBS52eW7332" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,694,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,694,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjj12dKP9sh9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpCRvgjRYLSh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zxMQC9c7dI61" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoj6RBPFLoUg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_zP7boueYFjq5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,179,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,179,667</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zXgBdXrgWH8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zisMqB94HX13" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,468,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,468,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_ztVj3P0n65pc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zsV0eKqopfK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zlFB9rLy3qp8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 298605 298605 68920535 68920535 69219140 69219140 1467753 1467753 226931 226931 1694684 1694684 10179667 10179667 58289066 58289066 68468733 68468733 2499147 2499147 233209 233209 2732356 2732356 <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z1i6M0IOOQb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zNYAyn9ogZLj" style="display: none">Schedule of Changes in the Fair Value Measurement</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20230101__20230331_zPNGGXqbtWqa" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_pp0p0_z70cJWxROCyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,732,356</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_zkQuanjP6Azf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of contingent consideration issued for business acquisitions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,037,672</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_z2bsUt4Xtv09" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,694,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2732356 -1037672 1694684 <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zzUN5jVpCpvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_z1bZKgSl0Dn" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zubiLC3gu1u7" style="width: 16%; text-align: right" title="Warrants measurement input">1.48</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zRGKyOegupSd" style="width: 16%; text-align: right" title="Warrants measurement input">2.52</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zVGmKsh9azW3" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zTsEq164e228" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHbJBjmr96If" title="Warrants measurement input">117.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zdyWNcht0oB8" title="Warrants measurement input">75.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zyz3v8lcghe8" title="Warrants measurement input">3.70</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zex4SwxUYfe5" title="Warrants measurement input">4.10</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230331_zC1tqhnOJPpk" title="Expected term">3.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_z5e46RI7VRm9" title="Expected term">4.0</span></td><td style="text-align: left"> </td></tr> </table> 1.48 2.52 9.13 9.13 1.1700 0.7500 0.0370 0.0410 P3Y9M18D P4Y <p id="xdx_804_eus-gaap--RevenueFromContractWithCustomerTextBlock_zyYNr5NyXUgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_820_zNSnltcNYd3l">Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zWew9sZ0AA11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zJwSO03Evjxc" style="display: none">Summary of Revenue by Geographic Area</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zbH74qUocNUi" style="width: 16%; text-align: right" title="Revenue">393,154</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220101__20220331__srt--StatementGeographicalAxis__country--US_zxlhwZaO8jfb" style="width: 16%; text-align: right" title="Revenue">14,218,398</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20230101__20230331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zL2pP77A2iOb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">208,803</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zGHtFgPhqfd8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">8,480,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20230101__20230331_zcoERvIyxTGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">601,957</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220101__20220331_zYTevBA3o2Sd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">22,699,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zrA5TFV5T8z2" style="text-align: right" title="Percentage of revenue">65</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zfiuZ6rjFLXj" style="text-align: right" title="Percentage of revenue">63</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zQreW55oMU0d" style="text-align: right" title="Percentage of revenue">35</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zzoL1tr0fukd" style="text-align: right" title="Percentage of revenue">37</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_z52KgoL0tdBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfRxJFgCyoJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zpnCj6xakcw9" style="display: none">Schedule of Deferred Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_c20230101__20230331_zP7dxrdxQrT" style="text-align: right" title="Deferred revenue, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Increase due to prepayments from customers</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20230101__20230331_zipdr1g77se6" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Increase due to prepayments from customers">18,120</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iE_c20230101__20230331_zYEodAjYZgU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, ending balance">18,120</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zMyjMGZpI7Gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zWew9sZ0AA11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zJwSO03Evjxc" style="display: none">Summary of Revenue by Geographic Area</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20230101__20230331__srt--StatementGeographicalAxis__country--US_zbH74qUocNUi" style="width: 16%; text-align: right" title="Revenue">393,154</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220101__20220331__srt--StatementGeographicalAxis__country--US_zxlhwZaO8jfb" style="width: 16%; text-align: right" title="Revenue">14,218,398</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20230101__20230331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zL2pP77A2iOb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">208,803</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zGHtFgPhqfd8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">8,480,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20230101__20230331_zcoERvIyxTGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">601,957</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220101__20220331_zYTevBA3o2Sd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">22,699,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zrA5TFV5T8z2" style="text-align: right" title="Percentage of revenue">65</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zfiuZ6rjFLXj" style="text-align: right" title="Percentage of revenue">63</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zQreW55oMU0d" style="text-align: right" title="Percentage of revenue">35</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220331__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zzoL1tr0fukd" style="text-align: right" title="Percentage of revenue">37</td><td style="text-align: left">%</td></tr> </table> 393154 14218398 208803 8480646 601957 22699044 0.65 0.63 0.35 0.37 <p id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfRxJFgCyoJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zpnCj6xakcw9" style="display: none">Schedule of Deferred Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_c20230101__20230331_zP7dxrdxQrT" style="text-align: right" title="Deferred revenue, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Increase due to prepayments from customers</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20230101__20230331_zipdr1g77se6" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Increase due to prepayments from customers">18,120</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iE_c20230101__20230331_zYEodAjYZgU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, ending balance">18,120</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 18120 18120 <p id="xdx_804_eus-gaap--EarningsPerShareTextBlock_zlj6ZCSyCl4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_82D_zOquAWFqXZIl">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUz7LwjqTsxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2023 and 2022, respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zLLTlWPHEtlc" style="display: none">Schedule of Basic and Diluted Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20230331_zHPzLYOd2qx8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220331_z2Bs5IHLGTt7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zsp6mX0K0txf" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net income, as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(5,755,391</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">11,714,595</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zFudWKNUJJDd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,483,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,935,570</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_z8qEcVGu0xO1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">775,906</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z3rzAqKA18Cj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,483,540</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">34,711,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_zJtBsebMLze7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.35</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_zWUGIbhh5r" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_z6iJjst25KT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, potentially dilutive securities of <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zMGmewGhpxu4" title="Securities excluded from computation of diluted earnings per share">1,271,304</span> were excluded from the calculation because their effect would have been anti-dilutive. The computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022, respectively, also excludes the approximately <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJzlH1WPdz7h" title="Securities excluded from computation of diluted earnings per share"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs0QopdJyR0j" title="Securities excluded from computation of diluted earnings per share">1.4</span></span> million shares of common stock and approximately <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEJWpogGzBje" title="Securities excluded from computation of diluted earnings per share">465,000</span> warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of incurring a net loss for the three months ended March 31, 2023, <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_uShares_c20230101__20230331_zn0bX4ujBAZ7" title="Securities excluded from computation of diluted earnings per share">no</span> potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of March 31, 2023, consisting of: (i) <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYyvJtXEtKk" title="Securities excluded from computation of diluted earnings per share">2,732,517</span> restricted stock units and (ii) <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zPZjpZcrlHKf" title="Securities excluded from computation of diluted earnings per share">120,445</span> options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUz7LwjqTsxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2023 and 2022, respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zLLTlWPHEtlc" style="display: none">Schedule of Basic and Diluted Earnings Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20230331_zHPzLYOd2qx8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220331_z2Bs5IHLGTt7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zsp6mX0K0txf" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net income, as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(5,755,391</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">11,714,595</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zFudWKNUJJDd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,483,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,935,570</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_z8qEcVGu0xO1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">775,906</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z3rzAqKA18Cj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,483,540</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">34,711,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_zJtBsebMLze7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.35</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_zWUGIbhh5r" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td></tr> </table> -5755391 11714595 29483540 33935570 775906 29483540 34711476 -0.20 0.35 -0.20 0.34 1271304 1400000 1400000 465000 0 2732517 120445 <p id="xdx_80C_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zKltyThPXU62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_821_zQ6t9PTzD2J6">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Incentive Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022, the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220831__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_z2poClLOf0C1" title="Number of common shares availalble for issuance">12,000,000</span> shares of common stock. The number of awards available for issuance under the Incentive Plan was <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_z79koya3PW5l" title="Number of common shares availalble for issuance">5,518,290</span> at March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zO8Zd1iCP8Af" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the three months ended March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zintvBJw8fy1" style="display: none">Schedule of Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230331_zfHP3P0Ts7Tj" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning">1,040,572</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zoc2yrUlFTe7" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331_zauVKUJsDdrc" style="width: 11%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zeLZAakVHatj" title="Weighted-average Remaining Contractual Life (years) Outstanding, Beginning">5.88</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20230331_z22ZCUm2bHt5" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_ztwxUnbSwQVl" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_zEvMwjeKp0d7" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230331_zT4zZyZJyW57" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zOpPmCT6KJwh" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20230331_zfH0jd6NEywl" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331_zNretVFPfox9" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230331_zOXl7jRCLiGl" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230101__20230331_zi8tpvAyVqSd" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230331_zQRwlD5gtjwk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zNtBNX5x2Lof" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_pid_c20230101__20230331_z8aq4rchAT7f" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230331_zbbMdVziB9F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_ztj33YEX1U3c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331_zepPPDcxJ6Pa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331_zUFW44oDfZ4c" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">5.64</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230331_zhYu76nsAeX7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zShU1LboNAog" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20230101__20230331_zQTNsjOwznrg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_zttgfaJ8lFD" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">5.64</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zsa7Z2ClzVWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value of outstanding options at March 31, 2023 was approximately $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zsLyXrGTMg18" title="Aggregate intrinsic value of outstanding options">0.3</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. As of March 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted Stock Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z2IyL5md9yD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zebqPcq1noZ" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p> <p style="margin-top: 0; margin-bottom: 0">RSUs</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Unvested at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztpZ3QperZk2" style="width: 16%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">2,426,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLoopDQO62Zh" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">6.95</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdoCg6tWn2I1" style="text-align: right" title="Number of Restricted Stock Units, Granted">692,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0OX4O0qYs1g" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpGH46v7ihY" style="text-align: right" title="Number of Restricted Stock Units, Vested">(68,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMHWJ8d9d4ej" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziCL7qQOBvnk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znefPYGbf0ca" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD8xUEeXVfh8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">3,050,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zH6lubOIjNGj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">5.94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zyDr08WANE7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, there was approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhTOVQu1fREe" title="Unrecognized stock-based compensation">14.5</span> million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCoL2uyGK5si" title="Unrecognized stock-based compensation recognition period">2.1</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zMRTEU3uIwOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the three months ended March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zu26b6NHI7Hk" style="display: none">Schedule of Warrant Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230331_zPd3JNo86JIl" style="width: 11%; text-align: right" title="Number of Warrants Outstanding, Beginning">485,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zpfUKfFcyN5k" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning">8.81</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue_iS_pid_c20230101__20230331_zXl6G29kIMD1" style="width: 11%; text-align: right" title="Weighted Average fair value, Beginning">2.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_zUluzTeyC5c" title="Weighted-average Remaining Contractual Life (Years) Outstanding">4.0</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331_zKHSHtDAfb62" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zmcW1bV7yP5k" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zUhHOkYYORxe" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20230331_z8TzVudN759d" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zpava0ED2Lib" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_pid_c20230101__20230331_z6GGBtO3iDL4" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20230331_ztDIczV0l3Vi" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zsiNjPvpdjw9" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zsXVw0g3zUF7" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_zN0xiswroGsc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zu93N6O63Kqf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zYEfFQdoPcF7" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at March 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230331_zvNWldS35rp1" style="text-align: right" title="Number of Warrants Outstanding, Ending">485,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zyXqdrGWia3c" style="text-align: right" title="Weighted Average Exercise Price, Ending">8.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331_zOtqKVebUS3c" style="text-align: right" title="Weighted Average Fair Value, Ending">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20230101__20230331_zdmPqTO17Aol" title="Weighted-average Remaining Contractual Life (Years) Outstanding">3.8</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zGIF46gwmt8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no warrants exercised during the three months ended March 31, 2023. The intrinsic value of warrants exercised during the three months ended March 31, 2022 was approximately $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN3Jar1mkrC6" title="Intrinsic value of warrants exercised">0.3</span> million. The aggregate intrinsic value of outstanding warrants at March 31, 2023 was approximately $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVH31pNGCyld" title="Aggregate intrinsic value of options outstanding">0.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of warrants exercisable at March 31, 2023 is <span id="xdx_902_ecustom--ClassOfWarrantExercisable_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSsSFrNELjsc" title="Warrants exercisable">20,000</span>. The ability to exercise the approximately <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLezIqDteCni" title="Warrants to purchase a common stock">465,000</span> warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation Expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zOEI5h10BdK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zm1CCt7UhSZi" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20230331_zkT4c0qWBng6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220101__20220331_zKFpOYL4fs0l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--CostOfSaleMember_zcprvrw45J56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cost of sales</p></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">12,008</p></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">12,327</p></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--SalesAndMarketingMember_zRFwtv0KsVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Sales and marketing</p></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">529,117</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">388,017</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--GeneralAndAdministrativeMember_zlOa9dnWpQYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1,192,214</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">765,199</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--ResearchAndDevelopmentMember_zhxY2r9RSpI1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">435,403</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">209,554</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zacwACkWCh46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,168,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,375,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zifEDrZoifvc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 12000000 5518290 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zO8Zd1iCP8Af" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the three months ended March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zintvBJw8fy1" style="display: none">Schedule of Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230331_zfHP3P0Ts7Tj" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning">1,040,572</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zoc2yrUlFTe7" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331_zauVKUJsDdrc" style="width: 11%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zeLZAakVHatj" title="Weighted-average Remaining Contractual Life (years) Outstanding, Beginning">5.88</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20230331_z22ZCUm2bHt5" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_ztwxUnbSwQVl" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331_zEvMwjeKp0d7" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230331_zT4zZyZJyW57" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zOpPmCT6KJwh" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20230331_zfH0jd6NEywl" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331_zNretVFPfox9" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230331_zOXl7jRCLiGl" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1029">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230101__20230331_zi8tpvAyVqSd" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230331_zQRwlD5gtjwk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zNtBNX5x2Lof" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_pid_c20230101__20230331_z8aq4rchAT7f" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230331_zbbMdVziB9F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_ztj33YEX1U3c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331_zepPPDcxJ6Pa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331_zUFW44oDfZ4c" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">5.64</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230331_zhYu76nsAeX7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zShU1LboNAog" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20230101__20230331_zQTNsjOwznrg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_zttgfaJ8lFD" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">5.64</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1040572 2.19 1.37 P5Y10M17D 1040572 2.19 1.37 P5Y7M20D 1040572 2.19 1.37 P5Y7M20D 300000 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z2IyL5md9yD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zebqPcq1noZ" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p> <p style="margin-top: 0; margin-bottom: 0">RSUs</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Unvested at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztpZ3QperZk2" style="width: 16%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">2,426,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLoopDQO62Zh" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">6.95</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdoCg6tWn2I1" style="text-align: right" title="Number of Restricted Stock Units, Granted">692,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0OX4O0qYs1g" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpGH46v7ihY" style="text-align: right" title="Number of Restricted Stock Units, Vested">(68,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMHWJ8d9d4ej" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziCL7qQOBvnk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znefPYGbf0ca" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD8xUEeXVfh8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">3,050,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zH6lubOIjNGj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">5.94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2426725 6.95 692500 2.82 68750 10.23 3050475 5.94 14500000 P2Y1M6D <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zMRTEU3uIwOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the three months ended March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zu26b6NHI7Hk" style="display: none">Schedule of Warrant Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230331_zPd3JNo86JIl" style="width: 11%; text-align: right" title="Number of Warrants Outstanding, Beginning">485,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zpfUKfFcyN5k" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning">8.81</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue_iS_pid_c20230101__20230331_zXl6G29kIMD1" style="width: 11%; text-align: right" title="Weighted Average fair value, Beginning">2.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_zUluzTeyC5c" title="Weighted-average Remaining Contractual Life (Years) Outstanding">4.0</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331_zKHSHtDAfb62" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zmcW1bV7yP5k" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zUhHOkYYORxe" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20230331_z8TzVudN759d" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zpava0ED2Lib" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_pid_c20230101__20230331_z6GGBtO3iDL4" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20230331_ztDIczV0l3Vi" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zsiNjPvpdjw9" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zsXVw0g3zUF7" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331_zN0xiswroGsc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zu93N6O63Kqf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zYEfFQdoPcF7" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at March 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230331_zvNWldS35rp1" style="text-align: right" title="Number of Warrants Outstanding, Ending">485,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zyXqdrGWia3c" style="text-align: right" title="Weighted Average Exercise Price, Ending">8.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331_zOtqKVebUS3c" style="text-align: right" title="Weighted Average Fair Value, Ending">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20230101__20230331_zdmPqTO17Aol" title="Weighted-average Remaining Contractual Life (Years) Outstanding">3.8</span></td><td style="text-align: left"> </td></tr> </table> 485000 8.81 2.43 P4Y 485000 8.81 1.09 P3Y9M18D 300000 100000 20000 465000 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zOEI5h10BdK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zm1CCt7UhSZi" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20230331_zkT4c0qWBng6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220101__20220331_zKFpOYL4fs0l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--CostOfSaleMember_zcprvrw45J56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cost of sales</p></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">12,008</p></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">12,327</p></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--SalesAndMarketingMember_zRFwtv0KsVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Sales and marketing</p></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">529,117</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">388,017</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--GeneralAndAdministrativeMember_zlOa9dnWpQYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1,192,214</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">765,199</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__custom--ResearchAndDevelopmentMember_zhxY2r9RSpI1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">435,403</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">209,554</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zacwACkWCh46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,168,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,375,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 12008 12327 529117 388017 1192214 765199 435403 209554 2168742 1375097 <p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zIPfpIX78Iwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_82F_zCwqNPjns9Vh">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">For the three months ended March 31, 2023, the Company recognized a benefit from income taxes of $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20230331_zSDbqfex9NG6" title="Income tax expense (benefit)">2,259,811</span>, representing an effective tax rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20230331_z4fNB0qwfdok" title="Effective income tax rate reconciliation, percent">28.2</span>%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20230331_z11z3n8LOsN1" title="Effective income tax rate reconciliation, percent">21.0</span>% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2022, the Company recognized expense from income taxes of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20220331_z93xLilIrjrc" title="Income tax expense (benefit)">1,386,087</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -2259811 0.282 0.210 1386087 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmByZj4GOe7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_82E_z4srGqWkAWyf">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease Obligations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases office space under a non-cancellable operating lease and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed. During the three months ended March 31, 2023, this lease was amended to extend the lease term. As a result of this amendment, the Company recognized an additional operating lease liability and corresponding operating right-of-use asset of $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zOAIjVWjhbFd" title="Operating lease right-of-use asset"><span id="xdx_905_eus-gaap--OperatingLeaseLiability_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zWImv4bo5kR7" title="Operating lease liabilities">657,150</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zBGdKyRfzmK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2023, components of lease expense are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z8J44ilbbvwi" style="display: none">Schedule of Lease Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230331_zgWqagZKjMPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_maLCz2lp_z5w4b715MHbj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 70%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">87,607</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_maLCz2lp_z4y3UG4TyUYd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">108,678</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LeaseCost_iT_mtLCz2lp_zMB6rAi5pIyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Total lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">196,285</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_z6uqEc4BRHZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease costs under month-to-month lease agreements are paid to related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2W4eNBn0nfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, the maturities of the Company’s lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zUOJuGa8Bv5" style="display: none">Schedule of Maturities on Company Lease Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230331_zEVFO2tQEVH9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz8za_zsxG53JaglN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 70%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">245,226</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz8za_zrmp9l1vdEx9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353,919</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz8za_zEOOL45dqUqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz8za_zE7hMxd00mRe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61,680</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz8za_zDXeH4IptLoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz8za_zXIq7mEa2SB4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz8za_zvSuNY3p6Mnk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,029,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zwyTipH64ii7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zZNOgy8RxhK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Present value of operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">935,427</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zD27IDrBoPTg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">277,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zKs7oI7UdV8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Long-term portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">658,137</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_z0nfQNmPiLM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_89C_ecustom--ScheduleOfOperatingLeaseTableTextBlock_zT3SDXKdoEgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zMjW6QyECWE" style="display: none">Schedule of Other Information Related to Operating Lease</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230101__20230331_zwocGFiCxema" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">March 31, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zv0Ix3vN9Xhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash paid for operating leases included in operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">188,835</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining lease term of operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zdj7NckFAbv4" title="Remaining lease term of operating leases">3</span> years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate of operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_zvMvivIZnM76" style="text-align: right" title="Discount rate of operating leases">6.7</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zBnJJ5XQXJnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two commercial litigation lawsuits in which plaintiffs are claiming they are owned certain remuneration based on alleged agreements with the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 657150 657150 <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zBGdKyRfzmK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2023, components of lease expense are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z8J44ilbbvwi" style="display: none">Schedule of Lease Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230331_zgWqagZKjMPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_maLCz2lp_z5w4b715MHbj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 70%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">87,607</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_maLCz2lp_z4y3UG4TyUYd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">108,678</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LeaseCost_iT_mtLCz2lp_zMB6rAi5pIyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Total lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">196,285</td><td style="text-align: left"> </td></tr> </table> 87607 108678 196285 <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2W4eNBn0nfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, the maturities of the Company’s lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zUOJuGa8Bv5" style="display: none">Schedule of Maturities on Company Lease Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230331_zEVFO2tQEVH9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz8za_zsxG53JaglN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 70%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">245,226</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz8za_zrmp9l1vdEx9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353,919</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz8za_zEOOL45dqUqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz8za_zE7hMxd00mRe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61,680</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz8za_zDXeH4IptLoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz8za_zXIq7mEa2SB4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz8za_zvSuNY3p6Mnk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,029,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zwyTipH64ii7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,689</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zZNOgy8RxhK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Present value of operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">935,427</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zD27IDrBoPTg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">277,290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zKs7oI7UdV8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Long-term portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">658,137</td><td style="text-align: left"> </td></tr> </table> 245226 353919 368291 61680 1029116 93689 935427 277290 658137 <p id="xdx_89C_ecustom--ScheduleOfOperatingLeaseTableTextBlock_zT3SDXKdoEgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zMjW6QyECWE" style="display: none">Schedule of Other Information Related to Operating Lease</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230101__20230331_zwocGFiCxema" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">March 31, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zv0Ix3vN9Xhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash paid for operating leases included in operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">188,835</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining lease term of operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zdj7NckFAbv4" title="Remaining lease term of operating leases">3</span> years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate of operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_zvMvivIZnM76" style="text-align: right" title="Discount rate of operating leases">6.7</td><td style="text-align: left">%</td></tr> </table> 188835 P3Y 0.067 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5JGqp6vkoz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_823_zeNV73eigDcc">Share Repurchase Program</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $<span id="xdx_901_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20220331_z2q6vekI1A4l" title="Stock repurchase program authorized amount">30.0</span> million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:</span></p> <p id="xdx_898_ecustom--ScheduleOfTreasuryStockTableTextBlock_zJ9hsCWysdhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zcM1RVGe4qfd" style="display: none">Schedule of Treasury Stock</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Balance, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--TreasuryStockCommonShares_iS_pid_d0_c20230101__20230331_zhbc3TteNJ39" style="width: 26%; text-align: right" title="Treasury stock, Beginning Balance">3,881,658</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Repurchases of common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--RepurchasesOfCommonStock_c20230101__20230331_zh0l65ksop8f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repurchases of common stock">309,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--TreasuryStockCommonShares_iE_pid_c20230101__20230331_zjqfQa0n3mDj" style="border-bottom: Black 2.5pt double; text-align: right" title="Treasury stock, Ending Balance">4,190,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zYxHuYmFqHjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 30000000.0 <p id="xdx_898_ecustom--ScheduleOfTreasuryStockTableTextBlock_zJ9hsCWysdhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zcM1RVGe4qfd" style="display: none">Schedule of Treasury Stock</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Balance, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--TreasuryStockCommonShares_iS_pid_d0_c20230101__20230331_zhbc3TteNJ39" style="width: 26%; text-align: right" title="Treasury stock, Beginning Balance">3,881,658</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Repurchases of common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--RepurchasesOfCommonStock_c20230101__20230331_zh0l65ksop8f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repurchases of common stock">309,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--TreasuryStockCommonShares_iE_pid_c20230101__20230331_zjqfQa0n3mDj" style="border-bottom: Black 2.5pt double; text-align: right" title="Treasury stock, Ending Balance">4,190,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3881658 309012 4190670 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zXQ48XLJqcCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_823_zvDRj6i6Dgsc">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p> Based on weighted-average useful life established as of the acquisition date. EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 120 285 1 true 43 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://codiagnostics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://codiagnostics.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://codiagnostics.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://codiagnostics.com/role/StatementOfStockholdersEquity Consolidated Statement of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Overview and Basis of Presentation Sheet http://codiagnostics.com/role/OverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Cash, Cash Equivalents, and Financial Instruments Sheet http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments Cash, Cash Equivalents, and Financial Instruments Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets, Net Sheet http://codiagnostics.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value Measurements Sheet http://codiagnostics.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 00000012 - Disclosure - Revenue Sheet http://codiagnostics.com/role/Revenue Revenue Notes 12 false false R13.htm 00000013 - Disclosure - Earnings Per Share Sheet http://codiagnostics.com/role/EarningsPerShare Earnings Per Share Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://codiagnostics.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Income Taxes Sheet http://codiagnostics.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://codiagnostics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Share Repurchase Program Sheet http://codiagnostics.com/role/ShareRepurchaseProgram Share Repurchase Program Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://codiagnostics.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Cash, Cash Equivalents, and Financial Instruments (Tables) Sheet http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstrumentsTables Cash, Cash Equivalents, and Financial Instruments (Tables) Tables http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments 20 false false R21.htm 00000021 - Disclosure - Intangible Assets, Net (Tables) Sheet http://codiagnostics.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://codiagnostics.com/role/IntangibleAssetsNet 21 false false R22.htm 00000022 - Disclosure - Fair Value Measurements (Tables) Sheet http://codiagnostics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://codiagnostics.com/role/FairValueMeasurements 22 false false R23.htm 00000023 - Disclosure - Revenue (Tables) Sheet http://codiagnostics.com/role/RevenueTables Revenue (Tables) Tables http://codiagnostics.com/role/Revenue 23 false false R24.htm 00000024 - Disclosure - Earnings Per Share (Tables) Sheet http://codiagnostics.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://codiagnostics.com/role/EarningsPerShare 24 false false R25.htm 00000025 - Disclosure - Stock-Based Compensation (Tables) Sheet http://codiagnostics.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://codiagnostics.com/role/Stock-basedCompensation 25 false false R26.htm 00000026 - Disclosure - Commitments and Contingencies (Tables) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://codiagnostics.com/role/CommitmentsAndContingencies 26 false false R27.htm 00000027 - Disclosure - Share Repurchase Program (Tables) Sheet http://codiagnostics.com/role/ShareRepurchaseProgramTables Share Repurchase Program (Tables) Tables http://codiagnostics.com/role/ShareRepurchaseProgram 27 false false R28.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies 28 false false R29.htm 00000029 - Disclosure - Schedule of Cash,Cash Equivalents and Marketable Investment Securities (Details) Sheet http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails Schedule of Cash,Cash Equivalents and Marketable Investment Securities (Details) Details 29 false false R30.htm 00000030 - Disclosure - Schedule of Intangible Assets, Net (Details) Sheet http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails Schedule of Intangible Assets, Net (Details) Details 30 false false R31.htm 00000031 - Disclosure - Schedule of Future Amortization Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails Schedule of Future Amortization Expense (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails Schedule of Fair Value Assets and Liabilities (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Changes in the Fair Value Measurement (Details) Sheet http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails Schedule of Changes in the Fair Value Measurement (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) Sheet http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails Schedule of Contingent Consideration Common Stock and Warrants (Details) Details 34 false false R35.htm 00000035 - Disclosure - Summary of Revenue by Geographic Area (Details) Sheet http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails Summary of Revenue by Geographic Area (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) Sheet http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails Schedule of Basic and Diluted Earnings Per Share (Details) Details 37 false false R38.htm 00000038 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://codiagnostics.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://codiagnostics.com/role/EarningsPerShareTables 38 false false R39.htm 00000039 - Disclosure - Schedule of Option Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOptionActivityDetails Schedule of Option Activity (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails Schedule of Recognized Stock-based Compensation Expense (Details) Details 42 false false R43.htm 00000043 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://codiagnostics.com/role/Stock-basedCompensationTables 43 false false R44.htm 00000044 - Disclosure - Income Taxes (Details Narrative) Sheet http://codiagnostics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://codiagnostics.com/role/IncomeTaxes 44 false false R45.htm 00000045 - Disclosure - Schedule of Lease Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails Schedule of Lease Expense (Details) Details 45 false false R46.htm 00000046 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails Schedule of Maturities on Company Lease Liabilities (Details) Details 46 false false R47.htm 00000047 - Disclosure - Schedule of Other Information Related to Operating Lease (Details) Sheet http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails Schedule of Other Information Related to Operating Lease (Details) Details 47 false false R48.htm 00000048 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://codiagnostics.com/role/CommitmentsAndContingenciesTables 48 false false R49.htm 00000049 - Disclosure - Schedule of Treasury Stock (Details) Sheet http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails Schedule of Treasury Stock (Details) Details 49 false false R50.htm 00000050 - Disclosure - Share Repurchase Program (Details Narrative) Sheet http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative Share Repurchase Program (Details Narrative) Details http://codiagnostics.com/role/ShareRepurchaseProgramTables 50 false false All Reports Book All Reports form10-q.htm codx-20230331.xsd codx-20230331_cal.xml codx-20230331_def.xml codx-20230331_lab.xml codx-20230331_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 622, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 120, "dts": { "calculationLink": { "local": [ "codx-20230331_cal.xml" ] }, "definitionLink": { "local": [ "codx-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "codx-20230331_lab.xml" ] }, "presentationLink": { "local": [ "codx-20230331_pre.xml" ] }, "schema": { "local": [ "codx-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 439, "entityCount": 1, "hidden": { "http://codiagnostics.com/20230331": 18, "http://fasb.org/us-gaap/2023": 141, "http://xbrl.sec.gov/dei/2023": 4, "total": 163 }, "keyCustom": 32, "keyStandard": 253, "memberCustom": 15, "memberStandard": 27, "nsprefix": "CODX", "nsuri": "http://codiagnostics.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://codiagnostics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Intangible Assets, Net", "menuCat": "Notes", "order": "10", "role": "http://codiagnostics.com/role/IntangibleAssetsNet", "shortName": "Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://codiagnostics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Revenue", "menuCat": "Notes", "order": "12", "role": "http://codiagnostics.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "13", "role": "http://codiagnostics.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "14", "role": "http://codiagnostics.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "15", "role": "http://codiagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://codiagnostics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Share Repurchase Program", "menuCat": "Notes", "order": "17", "role": "http://codiagnostics.com/role/ShareRepurchaseProgram", "shortName": "Share Repurchase Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "18", "role": "http://codiagnostics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CODX:ReclassificationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "19", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CODX:ReclassificationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://codiagnostics.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Cash, Cash Equivalents, and Financial Instruments (Tables)", "menuCat": "Tables", "order": "20", "role": "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstrumentsTables", "shortName": "Cash, Cash Equivalents, and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Intangible Assets, Net (Tables)", "menuCat": "Tables", "order": "21", "role": "http://codiagnostics.com/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "22", "role": "http://codiagnostics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "23", "role": "http://codiagnostics.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "24", "role": "http://codiagnostics.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "25", "role": "http://codiagnostics.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "26", "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CODX:ScheduleOfTreasuryStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Share Repurchase Program (Tables)", "menuCat": "Tables", "order": "27", "role": "http://codiagnostics.com/role/ShareRepurchaseProgramTables", "shortName": "Share Repurchase Program (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CODX:ScheduleOfTreasuryStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecuritiesDebtAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Cash,Cash Equivalents and Marketable Investment Securities (Details)", "menuCat": "Details", "order": "29", "role": "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails", "shortName": "Schedule of Cash,Cash Equivalents and Marketable Investment Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecuritiesDebtAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://codiagnostics.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Intangible Assets, Net (Details)", "menuCat": "Details", "order": "30", "role": "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails", "shortName": "Schedule of Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Future Amortization Expense (Details)", "menuCat": "Details", "order": "31", "role": "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails", "shortName": "Schedule of Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details)", "menuCat": "Details", "order": "32", "role": "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails", "shortName": "Schedule of Fair Value Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Changes in the Fair Value Measurement (Details)", "menuCat": "Details", "order": "33", "role": "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "shortName": "Schedule of Changes in the Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details)", "menuCat": "Details", "order": "34", "role": "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "shortName": "Schedule of Contingent Consideration Common Stock and Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Summary of Revenue by Geographic Area (Details)", "menuCat": "Details", "order": "35", "role": "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "shortName": "Summary of Revenue by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "CODX:IncreaseDueToPrepaymentsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Deferred Revenue (Details)", "menuCat": "Details", "order": "36", "role": "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails", "shortName": "Schedule of Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "CODX:IncreaseDueToPrepaymentsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details)", "menuCat": "Details", "order": "37", "role": "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Schedule of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Earnings Per Share (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "shortName": "Earnings Per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Option Activity (Details)", "menuCat": "Details", "order": "39", "role": "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "shortName": "Schedule of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "menuCat": "Details", "order": "40", "role": "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "shortName": "Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Warrant Activity (Details)", "menuCat": "Details", "order": "41", "role": "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails", "shortName": "Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "42", "role": "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "shortName": "Schedule of Recognized Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_us-gaap_WarrantMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Stock-Based Compensation (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_us-gaap_WarrantMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Lease Expense (Details)", "menuCat": "Details", "order": "45", "role": "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails", "shortName": "Schedule of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details)", "menuCat": "Details", "order": "46", "role": "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails", "shortName": "Schedule of Maturities on Company Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfOperatingLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Schedule of Other Information Related to Operating Lease (Details)", "menuCat": "Details", "order": "47", "role": "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails", "shortName": "Schedule of Other Information Related to Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfOperatingLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Commitments and Contingencies (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_LeaseAmendmentMember", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Schedule of Treasury Stock (Details)", "menuCat": "Details", "order": "49", "role": "http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails", "shortName": "Schedule of Treasury Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfTreasuryStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "lang": null, "name": "CODX:RepurchasesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://codiagnostics.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Share Repurchase Program (Details Narrative)", "menuCat": "Details", "order": "50", "role": "http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative", "shortName": "Share Repurchase Program (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://codiagnostics.com/role/StatementOfStockholdersEquity", "shortName": "Consolidated Statement of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Overview and Basis of Presentation", "menuCat": "Notes", "order": "7", "role": "http://codiagnostics.com/role/OverviewAndBasisOfPresentation", "shortName": "Overview and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Cash, Cash Equivalents, and Financial Instruments", "menuCat": "Notes", "order": "9", "role": "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments", "shortName": "Cash, Cash Equivalents, and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "CODX_ClassOfWarrantExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant exercisable.", "label": "Warrants exercisable" } } }, "localname": "ClassOfWarrantExercisable", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_ContingentConsideredIssuedForBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent considered issued for business acquisitions.", "label": "Change in fair value of contingent consideration issued for business acquisitions" } } }, "localname": "ContingentConsideredIssuedForBusinessAcquisitions", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "CODX_CostOfSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost Of Sale [Member]" } } }, "localname": "CostOfSaleMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "CODX_CustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers [Member]", "label": "Customers [Member]" } } }, "localname": "CustomersMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_CustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers Together [Member]", "label": "Customers Together [Member]" } } }, "localname": "CustomersTogetherMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_FairValueOfContingentConsiderationToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration to common stock.", "label": "Contingent consideration - common stock" } } }, "localname": "FairValueOfContingentConsiderationToCommonStock", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_FairValueOfContingentConsiderationToWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contigent consideration to warrants.", "label": "Contingent consideration - warrants" } } }, "localname": "FairValueOfContingentConsiderationToWarrants", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_FourCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Customers [Member]", "label": "Four Customers [Member]" } } }, "localname": "FourCustomersMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_GainOnRemeasurementOfAcquisitionContingencies": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on remeasurement of acquisition contingencies.", "label": "Gain on remeasurement of acquisition contingencies", "negatedLabel": "Change in fair value of acquisition contingencies" } } }, "localname": "GainOnRemeasurementOfAcquisitionContingencies", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "CODX_GeneralAndAdministrativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General And Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "CODX_IncreaseDueToPrepaymentsFromCustomers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase due to prepayments from customers.", "label": "Increase due to prepayments from customers" } } }, "localname": "IncreaseDueToPrepaymentsFromCustomers", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "CODX_IndefiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indefinite lived intangible asset useful life.", "label": "Estimated useful lives in years, term" } } }, "localname": "IndefiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "CODX_LeaseAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Amendment [Member]", "label": "Lease Amendment [Member]" } } }, "localname": "LeaseAmendmentMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_MeasurementInputStrikePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Strike Price [Member]", "label": "Measurement Input Strike Price [Member]" } } }, "localname": "MeasurementInputStrikePriceMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash lease expense.", "label": "Non-cash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash inventory moved to property plant and equipment..", "label": "Inventory moved to property, plant and equipment" } } }, "localname": "NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_OneCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Customers [Member]", "label": "One Customers [Member]" } } }, "localname": "OneCustomersMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_ReclassificationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassifications Policy [Text [Block]", "label": "Reclassifications" } } }, "localname": "ReclassificationsPolicyTextBlock", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "CODX_RepurchasesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchases of common stock.", "label": "Repurchases of common stock" } } }, "localname": "RepurchasesOfCommonStock", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails" ], "xbrltype": "sharesItemType" }, "CODX_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research And Development [Member]" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "CODX_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of World [Member]", "label": "Rest of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "CODX_SalesAndMarketingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales And Marketing [Member]" } } }, "localname": "SalesAndMarketingMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "CODX_ScheduleOfOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Operating Lease [Table Text Block]", "label": "Schedule of Other Information Related to Operating Lease" } } }, "localname": "ScheduleOfOperatingLeaseTableTextBlock", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "CODX_ScheduleOfTreasuryStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Treasury Stock [Table Text Block]", "label": "Schedule of Treasury Stock" } } }, "localname": "ScheduleOfTreasuryStockTableTextBlock", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgramTables" ], "xbrltype": "textBlockItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value, exercised.", "label": "Weighted Average Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Weighted Average Exercise Price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average fair value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue", "periodStartLabel": "Weighted Average fair value, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of warrants exercised.", "label": "Intrinsic value of warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, forfeited/cancelled.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, forfeited/cancelled.", "label": "Weighted Average Exercise Price, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price granted.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average remaining contractual life (years) outstanding, beginning.", "label": "Weighted-average Remaining Contractual Life (Years) Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term3.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3", "verboseLabel": "Weighted-average Remaining Contractual Life (Years) Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value, beginning.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "periodEndLabel": "Weighted Average Fair Value, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised.", "label": "Weighted Average Fair Value, Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value, forfeited/cancelled.", "label": "Weighted Average Fair Value, Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant date fair value, granted", "label": "Weighted Average Fair Value, Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "periodEndLabel": "Weighted Average Fair Value, Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised.", "label": "Weighted Average Fair Value Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.", "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TaxesPayableNoncurrent": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Taxes payable non current.", "label": "Income taxes payable" } } }, "localname": "TaxesPayableNoncurrent", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "CODX_ThreeCustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Customers Together [Member]", "label": "Three Customers Together [Member]" } } }, "localname": "ThreeCustomersTogetherMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoCustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers Together [Member]", "label": "Two Customers Together [Member]" } } }, "localname": "TwoCustomersTogetherMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoThousandFifteenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Long Term Incentive Plan [Member]", "label": "2015 Long Term Incentive Plan [Member]" } } }, "localname": "TwoThousandFifteenLongTermIncentivePlanMember", "nsuri": "http://codiagnostics.com/20230331", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r589", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r215", "r557", "r626", "r667", "r668" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r215", "r557", "r626", "r667", "r668" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r213", "r214", "r465", "r466", "r467", "r519", "r520", "r521", "r522", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r556", "r569", "r626", "r667" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r213", "r214", "r465", "r466", "r467", "r519", "r520", "r521", "r522", "r529", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r556", "r569", "r626", "r667" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27", "r566" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r140", "r216", "r217", "r545" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, before allowance for credit loss, current" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r216", "r217" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net", "verboseLabel": "Accounts receivable, after allowance for credit loss, current" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses, current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r35", "r85", "r141", "r427", "r442", "r443" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r4", "r13", "r35", "r367", "r370", "r404", "r438", "r439", "r606", "r607", "r608", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r80", "r566", "r670" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r328", "r329", "r330", "r453", "r614", "r615", "r616", "r655", "r671" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r326", "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r142", "r220", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Uncollectable accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Securities excluded from computation of diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r654" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.", "label": "Contingent consideration liabilities, current" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r654" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.", "label": "Contingent consideration liabilities" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r111", "r135", "r168", "r199", "r206", "r210", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r362", "r364", "r384", "r422", "r488", "r566", "r577", "r623", "r624", "r661" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r130", "r145", "r168", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r362", "r364", "r384", "r566", "r623", "r624", "r661" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r2", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "periodEndLabel": "Fair value as of March 31, 2023", "periodStartLabel": "Fair value as of December 31, 2022" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r73", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Overview and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/OverviewAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r38", "r133", "r543" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Financial Instruments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r38", "r95", "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r3", "r95" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r124", "r137", "r138", "r139", "r168", "r186", "r187", "r189", "r191", "r197", "r198", "r224", "r240", "r242", "r243", "r244", "r247", "r248", "r251", "r252", "r254", "r257", "r263", "r384", "r447", "r448", "r449", "r450", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r476", "r497", "r514", "r523", "r524", "r525", "r526", "r527", "r598", "r611", "r617" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants to purchase a common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r68", "r424", "r475" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r105", "r238", "r239", "r531", "r622" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r567", "r568", "r569", "r571", "r572", "r573", "r574", "r614", "r615", "r655", "r669", "r671" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r79", "r476" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r79", "r476", "r494", "r671", "r672" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r79", "r426", "r566" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 34,823,015 shares issued and 30,632,345 shares outstanding as of March 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r36", "r150", "r152", "r158", "r417", "r434" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r43", "r46", "r65", "r66", "r215", "r530" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r43", "r46", "r65", "r66", "r215", "r444", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r43", "r46", "r65", "r66", "r215", "r530", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r71", "r120" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations Risk and Significant Customers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r43", "r46", "r65", "r66", "r215" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage", "verboseLabel": "Percentage of revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r43", "r46", "r65", "r66", "r215", "r530" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Schedule of Deferred Revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r266", "r267", "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, ending balance", "periodStartLabel": "Deferred revenue, beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r266", "r267", "r286" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r251", "r252", "r254", "r571", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r91", "r168", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r384", "r623" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r44", "r215" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r8", "r109", "r121", "r355", "r356", "r613" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r341", "r342", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r8", "r53" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r8", "r202" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r285", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r285", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r10", "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r159", "r175", "r176", "r177", "r178", "r179", "r184", "r186", "r189", "r190", "r191", "r195", "r374", "r375", "r418", "r435", "r550" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic", "verboseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r159", "r175", "r176", "r177", "r178", "r179", "r186", "r189", "r190", "r191", "r195", "r374", "r375", "r418", "r435", "r550" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted", "verboseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r183", "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate reconciliation, percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r169", "r344", "r357" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Effective income tax rate reconciliation, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized stock-based compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r14", "r128", "r154", "r155", "r156", "r170", "r171", "r172", "r174", "r180", "r182", "r196", "r225", "r226", "r265", "r328", "r329", "r330", "r351", "r352", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r385", "r387", "r388", "r389", "r390", "r391", "r404", "r438", "r439", "r440", "r453", "r514" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r6", "r67", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity-Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r377", "r378", "r382" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r377", "r378", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r24", "r63", "r64", "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Schedule of Changes in the Fair Value Measurement" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Contingent Consideration Common Stock and Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r63", "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value Assets and Liabilities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r249", "r288", "r289", "r290", "r291", "r292", "r293", "r378", "r407", "r408", "r409", "r553", "r554", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r377", "r378", "r380", "r381", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r249", "r288", "r293", "r378", "r407", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r249", "r288", "r293", "r378", "r408", "r553", "r554", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r249", "r288", "r289", "r290", "r291", "r292", "r293", "r378", "r409", "r553", "r554", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r249", "r288", "r289", "r290", "r291", "r292", "r293", "r407", "r408", "r409", "r553", "r554", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r376", "r383" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r12", "r125", "r126", "r127", "r142", "r227", "r228", "r230", "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Allowance for Credit Losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful lives in years" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r134", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r103" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r103" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r234", "r235", "r236", "r237", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r102", "r414" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r50", "r52" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r102", "r413" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r610" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "(Loss) on disposition of assets", "negatedLabel": "Loss on disposition of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r8" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (loss) on equity method investment in joint venture", "negatedLabel": "(Gain) loss from equity method investment" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r92", "r499" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r45", "r530" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Intangible Assets, Net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r11", "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r90", "r168", "r199", "r205", "r209", "r211", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r384", "r552", "r623" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r1", "r86", "r113", "r199", "r205", "r209", "r211", "r419", "r431", "r552" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r169", "r338", "r345", "r346", "r349", "r353", "r358", "r359", "r360", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r122", "r181", "r182", "r203", "r343", "r354", "r437" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision (benefit)", "negatedLabel": "Income tax expense (benefit)", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r153", "r339", "r340", "r346", "r347", "r348", "r350", "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReceivable": { "auth_ref": [ "r602" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.", "label": "Income taxes receivable" } } }, "localname": "IncomeTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r7" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r7" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r7" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r410", "r609" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r7" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r7" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r49", "r51" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r161", "r163", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, finished goods, gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r144", "r544", "r566" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r119", "r132", "r143", "r231", "r232", "r233", "r411", "r547" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r604" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, raw materials, gross" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r396", "r565" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Schedule of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Maturities on Company Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r403" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r168", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r363", "r364", "r365", "r384", "r474", "r551", "r577", "r623", "r661", "r662" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r84", "r112", "r429", "r566", "r612", "r621", "r658" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30", "r131", "r168", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r363", "r364", "r365", "r384", "r566", "r623", "r661", "r662" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r26", "r74", "r75", "r76", "r77", "r168", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r363", "r364", "r365", "r384", "r623", "r661", "r662" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r69", "r601" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "verboseLabel": "Marketable securities (U.S. treasury bills and notes)" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r601" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable investment securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Investment Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Total Unrealized Gains / (Losses)" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r162" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r162" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r95", "r96", "r97" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r87", "r97", "r114", "r129", "r148", "r151", "r156", "r168", "r173", "r175", "r176", "r177", "r178", "r181", "r182", "r188", "r199", "r205", "r209", "r211", "r224", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r375", "r384", "r432", "r496", "r512", "r513", "r552", "r575", "r623" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net (loss) income", "terseLabel": "Net income, as reported", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementOfStockholdersEquity", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing transactions" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r216", "r217", "r415" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "Note receivable" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r199", "r205", "r209", "r211", "r552" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r397", "r565" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r393" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current", "verboseLabel": "Less: current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r393" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability", "verboseLabel": "Long-term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r394", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for operating leases included in operating cash flows" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r392" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r402", "r565" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Discount rate of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r401", "r565" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r157", "r385", "r386", "r391", "r416", "r433", "r606", "r607" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Total other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r14", "r25", "r149", "r152", "r157", "r385", "r386", "r391", "r416", "r433", "r606", "r607" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r146", "r147", "r222" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Change in net unrealized gains on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r37" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r620" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r567", "r568", "r571", "r572", "r573", "r574", "r669", "r671" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r78", "r251" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r78", "r476" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible preferred stock , shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r78", "r251" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r78", "r476", "r494", "r671", "r672" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r78", "r425", "r566" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r605" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r5" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from exercise of options and warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of marketable investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r420", "r430", "r566" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r160", "r229" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r666" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Investment in joint venture" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r436" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized gain on investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r72", "r337", "r663" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r81", "r107", "r428", "r441", "r443", "r451", "r477", "r566" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r170", "r171", "r172", "r174", "r180", "r182", "r225", "r226", "r328", "r329", "r330", "r351", "r352", "r366", "r368", "r369", "r371", "r373", "r438", "r440", "r453", "r671" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r200", "r201", "r204", "r207", "r208", "r212", "r213", "r215", "r284", "r285", "r412" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r200", "r201", "r204", "r207", "r208", "r212", "r213", "r215", "r284", "r285", "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r123", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r541" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Deferred Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r123", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r498", "r541", "r548" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r400", "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r215", "r599" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Schedule of Cash,Cash Equivalents and Marketable Investment Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r50", "r52", "r413" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r50", "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible Assets, Net" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r47", "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Summary of Revenue by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r22", "r23", "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Recognized Stock-based Compensation Expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Outstanding Restricted Stock Units and Related Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r22", "r23", "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r7" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Number of Restricted Stock Units, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Weighted Average Grant Date Fair Value, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Number of Restricted Stock Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Restricted Stock Units, Outstanding Ending", "periodStartLabel": "Number of Restricted Stock Units, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding Ending", "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Restricted Stock Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Number of Warrants Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Number of Warrants Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r16", "r17" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants Outstanding, Ending", "periodStartLabel": "Number of Warrants Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of common shares availalble for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Number of Options Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of Options Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted Average Fair Value Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options Outstanding, Ending", "periodStartLabel": "Number of Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r294", "r300", "r319", "r320", "r321", "r322", "r325", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years), Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted Average Fair Value Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Fair Value Outstanding, Ending", "periodStartLabel": "Weighted Average Fair Value Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Fair Value Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r398", "r565" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r124", "r137", "r138", "r139", "r168", "r186", "r187", "r189", "r191", "r197", "r198", "r224", "r240", "r242", "r243", "r244", "r247", "r248", "r251", "r252", "r254", "r257", "r263", "r384", "r447", "r448", "r449", "r450", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r476", "r497", "r514", "r523", "r524", "r525", "r526", "r527", "r598", "r611", "r617" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r14", "r33", "r128", "r154", "r155", "r156", "r170", "r171", "r172", "r174", "r180", "r182", "r196", "r225", "r226", "r265", "r328", "r329", "r330", "r351", "r352", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r385", "r387", "r388", "r389", "r390", "r391", "r404", "r438", "r439", "r440", "r453", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r170", "r171", "r172", "r196", "r412", "r445", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r493", "r495", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r514", "r570" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r170", "r171", "r172", "r196", "r412", "r445", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r493", "r495", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r514", "r570" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r78", "r79", "r107", "r306" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued for option exercises, shares", "negatedLabel": "Number of Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r14", "r33", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued for option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock repurchase program authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r14", "r78", "r79", "r107", "r453", "r514", "r526", "r576" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchases of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r79", "r82", "r83", "r100", "r478", "r494", "r515", "r516", "r566", "r577", "r612", "r621", "r658", "r671" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r106", "r167", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r265", "r372", "r517", "r518", "r528" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Share Repurchase Program" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r115", "r116", "r117", "r218", "r219", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r69", "r136", "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Fair Value" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradingSecuritiesDebtAmortizedCost": { "auth_ref": [ "r421", "r601" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investments in debt securities classified as trading.", "label": "Adjusted Cost" } } }, "localname": "TradingSecuritiesDebtAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury stock, shares", "periodEndLabel": "Treasury stock, Ending Balance", "periodStartLabel": "Treasury stock, Beginning Balance" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical", "http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r32", "r54", "r55" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 4,190,670 and 3,881,658 shares held as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r549", "r562", "r564", "r665" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashcashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r567", "r568", "r571", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive effect of stock options, warrants and RSUs" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r185", "r191" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Shares used to compute diluted earnings per share", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r184", "r191" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares, basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r579": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r581": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r582": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r583": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r584": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r585": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r586": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r587": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r588": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r589": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r591": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r592": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r593": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r594": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r595": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r596": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r597": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 68 0001493152-23-016425-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-016425-xbrl.zip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�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